Page last updated: 2024-12-05

granisetron

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Granisetron is a selective 5-HT3 receptor antagonist used to prevent and treat nausea and vomiting associated with chemotherapy, radiation therapy, and postoperative nausea and vomiting. It works by blocking the action of serotonin (5-HT) at the 5-HT3 receptors in the gastrointestinal tract. Granisetron is typically administered intravenously, orally, or rectally. The synthesis of granisetron involves a multi-step process starting from commercially available starting materials. Granisetron has been shown to be effective in reducing the incidence and severity of nausea and vomiting in various clinical trials. Its importance lies in improving the quality of life for patients undergoing cancer treatment or surgery. The study of granisetron is ongoing to understand its mechanisms of action, explore potential new indications, and develop safer and more effective antiemetics.'
```

Granisetron: A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic for cancer chemotherapy patients. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

granisetron : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 1-methyl-1H-indazole-3-carboxylic acid with the primary amino group of (3-endo)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine. A selective 5-HT3 receptor antagonist, it is used (generally as the monohydrochloride salt) to manage nausea and vomiting caused by cancer chemotherapy and radiotherapy, and to prevent and treat postoperative nausea and vomiting. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5284566
CHEMBL ID1290003
CHEMBL ID399538
CHEBI ID5537
CHEBI ID94501
SCHEMBL ID34178
SCHEMBL ID4891
SCHEMBL ID4890
MeSH IDM0026935
PubMed CID3510
CHEMBL ID519643
CHEMBL ID289469
CHEBI ID184693
SCHEMBL ID445223
MeSH IDM0026935

Synonyms (123)

Synonym
AB00918713-07
gtpl2300
1-methyl-n-[(1s,5r)-9-methyl-9-azabicyclo[3.3.1]nonan-7-yl]indazole-3-carboxamide
brl-43694
sancuso
1-methyl-n-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1h-indazole-3-carboxamide
kytril
granisetron (jan/usan/inn)
D04370
sancuso (tn)
granisetron
C07023
DB00889
brl 43964
1-methyl-n-(9-methyl-endo-9-azabicyclo(3.3.1)non-3-yl)-1h-indazole-3-carboxamide
1h-indazole-3-carboxamide, 1-methyl-n-(9-methyl-9-azabicyclo(3.3.1)non-3-yl)-, endo-
ly-278584
A802101
brl 43694; brl43694a;1-methyl-n-[(1s,5r)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide
apf530
1-methyl-n-[(1s,5r)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide
sustol
wzg3j2mcol ,
granisetron [usan:inn:ban:jan]
apf 530
unii-wzg3j2mcol
kevatril
granisetronum
bdbm50443668
1-methyl-n-[(1r,5s)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]indazole-3-carboxamide
CWB ,
S5052
granisetron [mi]
granisetron [inn]
granisetron [usan]
granisetron [usp monograph]
124998-65-8
granisetron [orange book]
granisetron [vandf]
1-methyl-n-(9-methyl-endo-9-azabicyclo[3.3.1]non-3-yl)-1h-indazole-3-carboxamide
granisetron [who-dd]
granisetron [jan]
granisetron [usp-rs]
CCG-221158
DL-166
SCHEMBL34178
SCHEMBL4891
SCHEMBL4890
chebi:5537 ,
CHEMBL1290003 ,
bdbm50449636
Q-101870
DTXSID0023111 ,
AKOS025402424
AC-8910
CHEBI:94501
SR-05000001492-1
sr-05000001492
SR-05000001492-2
9-azabicyclo[3.3.1]nonane, 1h-indazole-3-carboxamide deriv.
HMS3715H17
Q596708
HMS3886G11
NCGC00388522-02
1-methyl-n-(9-methyl-9-azabicyclo[3.3.1]nonan-7-yl)indazole- 3-carboxamide
granisetron (ab-1001)
CHEMBL399538
exo-granisetron
Z1501485362
EN300-1715980
LS-14665
AB01274752-01
[3h]-granisetron
1-methyl-n-(9-methyl-9-azabicyclo[3.3.1]nonan-7-yl)indazole-3-carboxamide
[3h]-brl-43694
gtpl2292
[3h]granisetron
PDSP2_001250
PDSP1_001266
109889-09-0
granisetronum [inn-latin]
brl 43694
NCGC00186041-01
L000281
1-methyl-n-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1h-indazole-3-carboxamide
1-methyl-1h-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide
1-methyl-1h-indazole-3-carboxylic acid (9-methyl-9-aza-bicyclo[3.3.1]non-3-yl)-amide(brl 43694)
(granisetron)1-methyl-1h-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide
bdbm50000483
1-methyl-1h-indazole-3-carboxylic acid (9-methyl-9-aza-bicyclo[3.3.1]non-3-yl)-amide
1-methyl-1h-indazole-3-carboxylic acid (9-methyl-9-aza-bicyclo[3.3.1]non-3-yl)-amide(granisetron)
(brl 43694)1-methyl-1h-indazole-3-carboxylic acid (9-methyl-9-aza-bicyclo[3.3.1]non-3-yl)-amide
2-(9-methyl-3,9-diaza-bicyclo[3.3.1]non-3-yl)-1-(1-methyl-1h-indol-3-yl)-ethanone(granisetron)
chembl519643
1-methyl-n-((1s,5r)-9-methyl-9-aza-bicyclo[3.3.1]nonan-3-yl)-1h-indazole-3-carboxamide
CHEBI:184693
1-methyl-n-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)indazole-3-carboxamide
1-methyl-n-{9-methyl-9-azabicyclo[3.3.1]nonan-3-yl}-1h-indazole-3-carboxamide
CHEMBL289469
apf-530
granisetron base
FT-0626805
AB07494
AKOS015895362
HY-B0071
CS-1509
SCHEMBL445223
MFWNKCLOYSRHCJ-UHFFFAOYSA-N
1-methyl-n-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-indazole-3-carboxamide
AB01274752_03
AB01274752_02
STL483411
EX-A1291
1364914-39-5
exo-granisetron (granisetron impurity f)
1224925-64-7
BCP10022
BBL036319
AA-504/10505045
SDCCGSBI-0633801.P001
NCGC00186041-09
1-methyl-n-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-1h-indazole-3-carboxamide
DTXSID50861188

Research Excerpts

Toxicity

Intravenous granisetron (20 micrograms/kg/dose) appears to be a safe and effective drug for pediatric patients receiving emetogenic chemotherapy. The most commonly reported adverse experiences were diarrhea, asthenia, and constipation. Only one adverse event, headache, occurred in more than five patients in the gran isetron group.

ExcerptReferenceRelevance
" Fewer patients receiving granisetron experienced adverse events (48% vs."( A single-blind study of the efficacy and safety of intravenous granisetron compared with alizapride plus dexamethasone in the prophylaxis and control of emesis in patients receiving 5-day cytostatic therapy. The Granisetron Study Group.
Bremer, K, 1992
)
0.28
" Only one adverse event, headache, occurred in more than five patients in the granisetron group."( Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group.
Chevallier, B, 1990
)
0.28
" The most frequently reported adverse events were constipation (n = 6) and headache (n = 5)."( An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease.
Carmichael, J; Forfar, C; Harris, AL; Philip, PA, 1995
)
0.29
" Granisetron (Kytril), which is a recently developed selective competitive inhibitor of the 5-HT3 receptor, was used for the treatment of these adverse effects, and was found to be clinically effective."( [Effective measures against side effects by increasing ACNU dose for malignant glioma: effects on digestive organs].
Imahori, T; Kasai, H; Kawamoto, K; Numa, Y; Tsuchida, T, 1994
)
0.29
" Safety analyses included incidence of adverse experiences and laboratory parameter changes."( Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.
Fitts, D; Gralla, RJ; Grunberg, SM; Kaplan, HG; Navari, RM; Palmer, R, 1994
)
0.29
" Headache was the most frequently reported adverse event (20%)."( Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.
Fitts, D; Gralla, RJ; Grunberg, SM; Kaplan, HG; Navari, RM; Palmer, R, 1994
)
0.29
" These findings suggest that M-VAC therapy is effective and safe when used in combination with these drugs."( [M-VAC chemotherapy for advanced urothelial cancer--side effects and their management].
Hosaka, M; Kondoh, K; Kubota, Y; Masuda, M; Misaki, H; Noguchi, S; Sakuramoto, T; Shuin, T; Yao, M, 1994
)
0.29
" antagonist) in children with malignant disease who had previously experienced unacceptable nausea and vomiting and/or adverse effects associated with standard antiemetic therapy."( The efficacy and safety of granisetron in pediatric cancer patients who had failed standard antiemetic therapy during anticancer chemotherapy.
Greenberg, M; Jacobson, SJ; Shore, RW; Spielberg, SP, 1994
)
0.29
" No serious adverse events occurred."( The efficacy and safety of granisetron in pediatric cancer patients who had failed standard antiemetic therapy during anticancer chemotherapy.
Greenberg, M; Jacobson, SJ; Shore, RW; Spielberg, SP, 1994
)
0.29
"Intravenous granisetron (20 micrograms/kg/dose) appears to be a safe and effective drug for pediatric patients receiving emetogenic chemotherapy."( The efficacy and safety of granisetron in pediatric cancer patients who had failed standard antiemetic therapy during anticancer chemotherapy.
Greenberg, M; Jacobson, SJ; Shore, RW; Spielberg, SP, 1994
)
0.29
" The overall incidence of adverse experiences was significantly lower in the granisetron group (60."( The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. The Granisetron Study Group.
, 1993
)
0.29
" Safety analyses consisted of adverse events and laboratory parameter changes."( Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis.
Fitts, D; Gralla, RJ; Grunberg, SM; Kaplan, HG; Navari, RM; Palmer, RH; Perez, EA, 1997
)
0.3
" Patients were evaluated for emetic episodes, extent of nausea, and adverse events for 7 days after the start of chemotherapy."( Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
Burris, H; Cohn, J; Fitts, D; Friedman, C; Hesketh, P; Moriconi, W; Ryan, T,
)
0.13
" Both regimens were well tolerated, with headache (36% for granisetron, 29% for prochlorperazine) and constipation (31% for granisetron, 6% for prochlorperazine) the most common adverse events."( Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
Burris, H; Cohn, J; Fitts, D; Friedman, C; Hesketh, P; Moriconi, W; Ryan, T,
)
0.13
" Multiple trials with different pharmacological agents and alternative anesthetic techniques have been used in an attempt to decrease this, but results have been inconclusive and adverse effects occur frequently."( The safety and efficacy of granisetron in postoperative vomiting in pediatric patients undergoing tonsillectomy.
Carnahan, D; Dato, K; Hartsuff, J, 1997
)
0.3
" Safety assessment was based on the type and frequency of adverse experiences reported by the patient at 24 and 48 hours after chemotherapy began."( Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Friedman, C; Kalman, L; Kaywin, P; Lembersky, B; Perez, EA; Yocom, K,
)
0.13
" No serious adverse events were observed in either administration group."( [Efficacy and safety of two methods of administration of granisetron injection for nausea and vomiting induced by chemotherapy for tumors in hematopoietic organs--a randomized crossover comparison between intravenous drip infusion and intravenous bolus in
Moriguchi, T; Tsudo, M, 1998
)
0.3
" Oral granisetron and ondansetron are safe and effective for the prevention of nausea and vomiting resulting from TBI."( Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation.
Bushnell, W; Frankel, SR; Friedman, CJ; Raschko, J; Spitzer, TR, 2000
)
0.31
" One patient experienced a life-threatening adverse reaction within minutes of receiving the first dose."( Pegylated liposomal doxorubicin: tolerability and toxicity.
Goram, AL; Richmond, PL, 2001
)
0.31
" The most commonly reported adverse experiences in granisetron-treated patients were diarrhea, asthenia, and constipation."( The efficacy and safety of once-daily Kytril (granisetron hydrochloride) tablets in the prophylaxis of nausea and emesis following fractionated upper abdominal radiotherapy.
Friedman, C; Lanciano, R; Michalski, J; Preston, AJ; Sherman, DM; Yocom, K, 2001
)
0.31
" Adverse events were self-assessed using a symptom checklist."( The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy.
Carmichael, J; Harris, AL, 2004
)
0.32
" Furthermore, in the 7 days following dosing there were no serious adverse events leading to withdrawal from the trial."( The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy.
Carmichael, J; Harris, AL, 2004
)
0.32
" Emetic episodes, doses of rescue medications to treat breakthrough nausea or vomiting, and occurrence of adverse events were recorded."( Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy.
Cartwright, J; Frangoul, H; Ho, RH; Jones, E; Koyama, T; Kuttesch, J; Shankar, S; Whitlock, JA, 2007
)
0.34
" Adverse events were mostly mild to moderate, with quite low rates among the two groups."( The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial.
Huang, Y; Liang, H; Liu, D; Liu, W; Si, X; Wang, L; Yu, Z; Zhang, H, 2009
)
0.35
" Safe use of granisetron as an antiemetic after skin prick, oral, and intravenous challenge tests is presented."( Anaphylactic reaction owing to ondansetron administration in a child with neuroblastoma and safe use of granisetron: a case report.
Batu, ED; Büyükpamukçu, M; Civelek, E; Demir, HA; Saçkesen, C; Yalçın, B, 2010
)
0.36
" We performed observational retrospective study to compare 1 mg/body with 3 mg/body of intravenous granisetron for the prevention of CINV and adverse events in hematological malignancy patients."( [Comparison of 1 mg/body and 3 mg/body of intravenous granisetron for the prevention of chemotherapy-induced nausea and vomiting and adverse events in hematological malignancy patients].
Hori, K; Kawakami, J; Motohashi, S; Ohnishi, K; Ono, T, 2012
)
0.38
" The rates of adverse drug events (ADEs) did not significantly differ between groups."( Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy.
Akashi, K; Egashira, N; Hiraiwa, H; Ichinose, K; Ikesue, H; Iwasaki, H; Kato, K; Miyamoto, T; Oishi, R; Sakurai, A; Takenaka, K; Teshima, T; Uchida, M, 2013
)
0.39
" The frequencies of adverse drug events (ADEs) were not significantly different between two groups."( Effectiveness and safety of antiemetic aprepitant in Japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation.
Akashi, K; Egashira, N; Hiraiwa, H; Ichinose, K; Ikesue, H; Iwasaki, H; Kato, K; Miyamoto, T; Muta, T; Oishi, R; Sakurai, A; Shiratsuchi, M; Suetsugu, K; Takenaka, K; Teshima, T; Uchida, M, 2013
)
0.39
" Rates of other frequently observed adverse drug events were similar between groups."( Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation.
Akashi, K; Egashira, N; Hiraiwa, H; Ichinose, K; Ikesue, H; Iwasaki, H; Kato, K; Miyamoto, T; Muta, T; Nagata, K; Oishi, R; Sakurai, A; Shiratsuchi, M; Suetsugu, K; Takenaka, K; Teshima, T; Uchida, M, 2013
)
0.39
"Triplet therapy using an increased-dose of DEX is suggested to be safe and effective for patients receiving HEC."( Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan.
Akashi, K; Arita, S; Ariyama, H; Baba, E; Komoda, M; Kumagai, H; Kusaba, H; Nagata, K; Nakano, M; Okumura, Y; Takaishi, S; Tamura, S; Uchida, M, 2014
)
0.4
"The purpose of this article is to outline the risk of cardiac adverse events (AEs) from 5-HT3-RAs, with focus on the three most commonly used, ondansetron, granisetron and palonosetron."( 5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.
Brygger, L; Herrstedt, J, 2014
)
0.4
" The incidence of treatment-related adverse events during cycles 2-6 was similar in rolapitant (5."( Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Arora, S; Chasen, M; Navari, R; Powers, D; Rapoport, B; Schnadig, I; Schwartzberg, L, 2016
)
0.43
" The most common adverse event was constipation."( Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double-blind, phase III study.
Chen, YX; Chen, ZD; Cheng, Y; Dang, CX; Dong, J; Han, BH; Hu, B; Li, BL; Li, JL; Liu, B; Lu, JG; Qin, SK; Shi, JH; Shu, YQ; Sun, XC; Wang, D; Wang, HB; Wang, KM; Wang, QM; Wu, Q; Yang, LQ; Zhang, HL; Zhang, QY; Zhang, ZH, 2017
)
0.46
" Laboratory and clinical adverse events were compared between the two cohorts."( Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies.
Cabanillas Stanchi, KM; Döring, M; Ebinger, M; Feucht, J; Handgretinger, R; Hartmann, U; Koch, MS; Lang, P; Lange, V; Malaval, C; Mezger, M; Michaelis, S; Ost, M; Queudeville, M; Schober, S; Weber, S, 2019
)
0.51
"Antiemetic prophylaxis with fosaprepitant and granisetron with or without dexamethasone was well tolerated, safe and effective in pediatric patients."( Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies.
Cabanillas Stanchi, KM; Döring, M; Ebinger, M; Feucht, J; Handgretinger, R; Hartmann, U; Koch, MS; Lang, P; Lange, V; Malaval, C; Mezger, M; Michaelis, S; Ost, M; Queudeville, M; Schober, S; Weber, S, 2019
)
0.51
" GTDS was safe and well tolerated."( Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety.
Console, G; Ferreri, A; Gentile, M; Gori, M; Loteta, B; Martino, M; Morabito, A; Moscato, T; Naso, V; Paviglianiti, A; Pitino, AL; Porto, G; Provenzano, PF; Rossi, M; Tripepi, G, 2020
)
0.56
"The aim of this study was to evaluate postoperative analgesia effectiveness and patient-controlled analgesia (PCA)-related adverse events."( Effectiveness of Sufentanil-Based Patient-Controlled Analgesia Regimen in Children and Incidence of Adverse Events Following Major Congenital Structure Repairs.
Liu, F; Xie, D; Zuo, Y, 2023
)
0.91
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32

Pharmacokinetics

Study evaluated the influence of polymorphisms in CYP3A4, CYP1A1, and ABCB1 on the pharmacokinetic properties of granisetron in pregnant women. We found no significant difference in the pharmacodynamic parameters of docetaxel between the single dose and the combination.

ExcerptReferenceRelevance
" Further exploration of its dose scheduling and pharmacokinetic profile is warranted."( A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response.
Cantwell, BM; Carmichael, J; Edwards, CM; Harris, AL; Rapeport, WG; Thompson, S; Zussman, BD, 1989
)
0.28
" Mean pharmacokinetic parameters in 14 patients in whom plasma assay data are available were: Maximum observed concentration = 30."( Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist.
Adams, L; Cassidy, J; Kaye, SB; Lewis, C; Raina, V; Rankin, EM; Rapeport, WG; Soukop, M; Zussman, BD, 1988
)
0.27
" The median values recorded for peak concentration (Cmax) and area under the curve (AUC) were 195 ng/ml and 71."( An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease.
Carmichael, J; Forfar, C; Harris, AL; Philip, PA, 1995
)
0.29
" Pharmacokinetic parameters and dose-normalised plasma levels appeared to be independent of dose in the range 50 to 300 micrograms."( Pharmacokinetics and tolerability of ascending intravenous doses of granisetron, a novel 5-HT3 antagonist, in healthy human subjects.
Allen, A; Asgill, CC; Pierce, DM; Upward, J; Zussman, BD, 1994
)
0.29
" Granisetron rapidly entered the extracellular fluid of cerebral frontal cortex at Tmax of 24 min."( Pharmacokinetics of granisetron in rat blood and brain by microdialysis.
Chen, CF; Huang, CT; Tsai, TH, 1999
)
0.3
" The pharmacokinetic parameters of GRN in child cancer patients varied markedly among individuals, and some child patients had smaller t(1/2beta) than adult patients."( Pharmacokinetics of granisetron in adults and children with malignant diseases.
Hirano, K; Honma, T; Mino, K; Nakabayashi, T; Saitoh, H; Sato, M; Takada, M; Takeda, T; Wada, I, 2001
)
0.31
"Two studies were conducted to determine whether concomitant administration of aprepitant altered the pharmacokinetic profiles of ondansetron and granisetron, two 5-HT(3)-receptor antagonists commonly used as antiemetic therapy for CINV."( Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects.
Blum, RA; Busillo, J; Goldberg, MR; Gottesdiener, KM; Greenberg, HE; Hesney, M; Hustad, CM; Kraft, WK; Lates, C; Majumdar, A; McCrea, J; Murphy, MG; Orlowski, LH; Panebianco, D; Petty, KJ; Van Buren, S; Waldman, SA, 2003
)
0.32
" Individual plasma samples were used to estimate area under the plasma concentration-time curve from time zero to infinity (AUC(0- infinity )), peak plasma concentration, and apparent terminal elimination half-life (t(12)) of both ondansetron and granisetron."( Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects.
Blum, RA; Busillo, J; Goldberg, MR; Gottesdiener, KM; Greenberg, HE; Hesney, M; Hustad, CM; Kraft, WK; Lates, C; Majumdar, A; McCrea, J; Murphy, MG; Orlowski, LH; Panebianco, D; Petty, KJ; Van Buren, S; Waldman, SA, 2003
)
0.32
"019), with no significant effect on peak concentration at the end of the infusion (360."( Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects.
Blum, RA; Busillo, J; Goldberg, MR; Gottesdiener, KM; Greenberg, HE; Hesney, M; Hustad, CM; Kraft, WK; Lates, C; Majumdar, A; McCrea, J; Murphy, MG; Orlowski, LH; Panebianco, D; Petty, KJ; Van Buren, S; Waldman, SA, 2003
)
0.32
"Concomitant administration of aprepitant had no clinically significant effect on the mean pharmacokinetic characteristics of either ondansetron or granisetron in these healthy subjects."( Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects.
Blum, RA; Busillo, J; Goldberg, MR; Gottesdiener, KM; Greenberg, HE; Hesney, M; Hustad, CM; Kraft, WK; Lates, C; Majumdar, A; McCrea, J; Murphy, MG; Orlowski, LH; Panebianco, D; Petty, KJ; Van Buren, S; Waldman, SA, 2003
)
0.32
"The primary route of elimination of granisetron is by oxidative hepatic metabolism, thus its pharmacokinetic profile may be altered by co-administration of other drugs that inhibit or induce hepatic drug metabolizing enzymes."( The effect of repeat dosing with cimetidine on the pharmacokinetics of intravenous granisetron in healthy volunteers.
Youlten, L, 2004
)
0.32
"We found no significant difference in the pharmacokinetic and pharmacodynamic parameters of docetaxel between the single dose of docetaxel and the combination of docetaxel and granisetron."( The influence of granisetron on the pharmacokinetics and pharmacodynamics of docetaxel in Asian lung cancer patients.
Burioka, N; Endo, M; Igishi, T; Kurai, J; Miyata, M; Morita, M; Shigeoka, Y; Shimizu, E; Suyama, H; Takane, H; Yasuda, K,
)
0.13
" Pharmacokinetic parameters observed with each administration route were compared by analysis of variance."( Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy.
Azanza, JR; Blanco-Prieto, MJ; Cabello, JP; Campanero, MA; Ceballos, J; de la Cruz, S; Fernandez Gallego, V; Garcia-Foncillas, J; Gil-Aldea, I; Gurpide, A; Lopez-Picazo, JM; Martin-Algarra, S; Olier Garate, C; Perez-Gracia, JL; Reyna, C; Sadaba, B, 2007
)
0.34
"To develop a population pharmacokinetic model of aprepitant and dexamethasone in Japanese patients with cancer, explore the factors that affect the pharmacokinetics of aprepitant, and evaluate the effect of aprepitant on the clearance of intravenous dexamethasone."( Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting.
Awata, H; Hashimoto, Y; Katayama, M; Kitagawa, J; Kodama, Y; Miyata, Y; Nakade, S; Ohno, T, 2008
)
0.35
"A pharmacokinetic model for aprepitant has been developed that incorporates body weight, age, ALT, BUN and aprepitant dose to predict the CL/F."( Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting.
Awata, H; Hashimoto, Y; Katayama, M; Kitagawa, J; Kodama, Y; Miyata, Y; Nakade, S; Ohno, T, 2008
)
0.35
" Log-transformed area under the curve (AUC) and Cmax were statistically analyzed by performing an analysis of variance."( Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron.
Adams, LM; Johnson, B; Kirby, LC; Lebowitz, P; Stoltz, R; Yue, L; Zhang, K, 2009
)
0.35
"To determine the pharmacokinetic (PK) profile of granisetron transdermal formulation and examine its possible relationship with age, gender, and renal function."( Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting.
Drenth, HJ; Gill, D; Howell, J; Smeets, J, 2009
)
0.35
" The method was applied to the comparative pharmacokinetic study of granisetron in Chinese healthy subjects."( A high-performance liquid chromatography-tandem mass spectrometry method coupled with protein precipitation for determination of granisetron in human plasma and its application to a comparative pharmacokinetic study.
Hu, P; Jiang, J; Wang, H; Zhou, Y, 2014
)
0.4
" This validated method was successfully applied to a pharmacokinetic study after intravenous administration of 1 mg granisetron to a pregnant subject."( Development and validation of a sensitive liquid chromatographic-tandem mass spectrometric method for the simultaneous analysis of granisetron and 7-hydroxy granisetron in human plasma and urine samples: application in a clinical pharmacokinetic study in
Caritis, S; Chen, HJ; Venkataramanan, R; Zhao, Y, 2016
)
0.43
"To select appropriate antiemetics relieving teriparatide-induced nausea and vomiting during osteoporosis treatment using PET molecular imaging and pharmacokinetic analysis."( Exploration of Antiemetics for Osteoporosis Therapy-Induced Nausea and Vomiting Using PET Molecular Imaging Analysis to Gastrointestinal Pharmacokinetics.
Cui, Y; Hayashinaka, E; Katayama, Y; Nakaoka, T; Okauchi, T; Onoe, K; Shingaki, T; Takashima, T; Wada, Y; Watanabe, Y, 2016
)
0.43
" Pharmacokinetic PET imaging data analysis quantitatively showed the pharmacological effects of teriparatide-induced suppression of upper gastrointestinal motility and its restoration by granisetron and mosapride."( Exploration of Antiemetics for Osteoporosis Therapy-Induced Nausea and Vomiting Using PET Molecular Imaging Analysis to Gastrointestinal Pharmacokinetics.
Cui, Y; Hayashinaka, E; Katayama, Y; Nakaoka, T; Okauchi, T; Onoe, K; Shingaki, T; Takashima, T; Wada, Y; Watanabe, Y, 2016
)
0.43
"This study evaluated the influence of polymorphisms in CYP3A4, CYP3A5, CYP1A1, and ABCB1 on the pharmacokinetic properties of granisetron in pregnant women."( Polymorphisms in CYP1A1 and CYP3A5 Genes Contribute to the Variability in Granisetron Clearance and Exposure in Pregnant Women with Nausea and Vomiting.
Bustos, ML; Caritis, SN; Chen, H; Venkataramanan, R; Zhao, Y, 2016
)
0.43
"Physiologically based pharmacokinetic modeling is considered a valuable tool for predicting pharmacokinetic changes in pregnancy to subsequently guide in-vivo pharmacokinetic trials in pregnant women."( A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.
Coboeken, K; Dallmann, A; Eissing, T; Hempel, G; Ince, I, 2018
)
0.48
"Quantitative information on gestation-specific changes in enzyme activity available in the literature was incorporated in a pregnancy physiologically based pharmacokinetic model and the pharmacokinetics of eight drugs metabolized via one or multiple cytochrome P450 enzymes was predicted."( A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.
Coboeken, K; Dallmann, A; Eissing, T; Hempel, G; Ince, I, 2018
)
0.48
"The pregnancy physiologically based pharmacokinetic model successfully predicted the pharmacokinetics of all tested drugs."( A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.
Coboeken, K; Dallmann, A; Eissing, T; Hempel, G; Ince, I, 2018
)
0.48
"The presented pregnancy physiologically based pharmacokinetic model can quantitatively predict the pharmacokinetics of drugs that are metabolized via one or multiple cytochrome P450 enzymes by integrating prior knowledge of the pregnancy-related effect on these enzymes."( A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.
Coboeken, K; Dallmann, A; Eissing, T; Hempel, G; Ince, I, 2018
)
0.48
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

Two Phase III trials compared the efficacy of palonosetron, ondansetron and granisetron combined with dexamethasone. The prevention of nausea, vomiting and appetite loss induced by remission induction chemotherapy for acute myeloid leukemia was compared.

ExcerptReferenceRelevance
") alone or in combination with haloperidol (0."( Effects produced by acute and chronic treatment with granisetron alone or in combination with haloperidol on midbrain dopamine neurons.
Ashby, CR; Minabe, Y; Wang, RY, 1992
)
0.28
" Oral granisetron in combination with a corticosteroid provides superior anti-emetic control to the met/dex regimen in patients undergoing highly emetogenic chemotherapy."( Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group.
Cedar, E; Cunningham, J; Goedhals, L; Heron, JF; Jordaan, JP, 1994
)
0.29
"Ondansetron 8mg and granisetron 3 mg, both combined with dexamethasone, showed similar efficacy and tolerability in the prevention of cisplatin-induced emesis."( Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research.
, 1995
)
0.29
" Granisetron and its combination with dexamethasone for the treatment of delayed emesis following cisplatin (CDDP) administration were investigated using ferrets."( Effects of granisetron and its combination with dexamethasone on cisplatin-induced delayed emesis in the ferret.
Endo, T; Fukunaka, N; Hirafuji, M; Kudo, R; Minami, M; Sagae, S, 1998
)
0.3
"The prevention of nausea, vomiting and appetite loss induced by remission induction chemotherapy for acute myeloid leukemia was compared by randomization between granisetron alone and combination with granisetron plus methylprednisolone."( [Efficacy of combination with granisetron and methylprednisolone for nausea, vomiting and appetite loss in remission induction chemotherapy of acute myeloid leukemia--a randomized comparative trial between granisetron alone and granisetron plus methylpred
Hirota, K; Kikuchi, H; Nakayama, T; Nasu, M; Ohno, E; Ohtuka, E; Ono, K; Saburi, Y; Uchida, I; Uno, N, 1999
)
0.3
" We designed a study to evaluate the efficacy of a setron (granisetron) in the delayed phase, compared with metoclopramide, each combined with a corticosteroid."( A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis.
Aapro, MS; Bernhard, J; De Pree, C; Maibach, R; Sessa, C; Thuerlimann, B, 2003
)
0.32
" This regimen is under way in which chemotherapy with 5-FU 500 mg/day on days 1 to 5 and superselective intra-arterial infusion of CDGP on day 6 combined with radiation therapy is being evaluated for locally advanced oral cancer."( [Clinical trial of chemotherapy by superselective intra-arterial infusion of nedaplatin combined with radiotherapy for advanced oral cancer].
Goto, M; Shikimori, M; Yamshita, Y, 2005
)
0.33
" This study was designed to compare the effectiveness of granisetron either alone or in combination with droperidol or dexamethasone, for the prevention of post operative nausea and vomiting (PONV) in patients undergoing laparoscopic bariatric surgeries."( Prevention of postoperative nausea and vomiting in patients undergoing laparoscopic bariatric surgery--granisetron alone vs granisetron combined with dexamethasone/droperidol.
Moussa, AA; Oregan, PJ, 2007
)
0.34
"Graniserton is effective and safe drug for reducing the incidence of PONV in patients undergoing bariatric surgeries, and becomes highly effective when combined with dexamethasone."( Prevention of postoperative nausea and vomiting in patients undergoing laparoscopic bariatric surgery--granisetron alone vs granisetron combined with dexamethasone/droperidol.
Moussa, AA; Oregan, PJ, 2007
)
0.34
"The aim of the study was to assess the toxicity and the clinical activity of biweekly oxaliplatin (OXA) in combination with continuous infusional 5-fluorouracil (5-FU) and leucovorin (LV) administered every 2 weeks (modified FOLFOX-4 regimen) in elderly patients with advanced gastric cancer (AGC)."( Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer.
Fu, Z; Guan, F; Guo, QS; Liu, ZF; Wang, MY; Yang, XG; Zhang, XQ, 2008
)
0.35
"A recently developed oral serotonergic challenge test consisting of 5-Hydroxytryptophane (5-HTP, 200 mg) combined with carbidopa (CBD, 100 mg + 50 mg) exhibited dose-related neuroendocrine responsiveness and predictable pharmacokinetics."( Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron.
de Kam, ML; Derijk, RH; Jacobs, GE; Kamerling, IM; van Gerven, JM; van Pelt, J; Zitman, FG, 2010
)
0.36
"Background Two pivotal Phase III trials compared the efficacy of palonosetron, ondansetron and granisetron, combined with dexamethasone, for the prevention of nausea and vomiting following highly emetogenic chemotherapy."( Economic evaluation of 5-HT3 receptor antagonists in combination with dexamethasone for the prevention of 'overall' nausea and vomiting following highly emetogenic chemotherapy in Chinese adult patients.
Du, Q; Xu, XL; Yu, B; Zhai, Q; Zhu, B, 2017
)
0.46
"A systematic review and meta-analysis of published randomized controlled trials was performed to update the present evidence about the safety and efficacy of dexamethasone combined with other antiemetics versus single antiemetics for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy."( Dexamethasone combined with other antiemetics versus single antiemetics for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: An updated systematic review and meta-analysis.
Abushouk, AI; Ahmed, H; Al Nahrawi, S; Attia, A; Awad, K; Elsherbeny, MY; Mustafa, SM, 2016
)
0.43
"Pooled data from 14 RCTs (1542 patients) favored dexamethasone combined with other antiemetics over single antiemetics as a prophylaxis against postoperative nausea and vomiting after laparoscopic cholecystectomy in the early postoperative period (OR = 0."( Dexamethasone combined with other antiemetics versus single antiemetics for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: An updated systematic review and meta-analysis.
Abushouk, AI; Ahmed, H; Al Nahrawi, S; Attia, A; Awad, K; Elsherbeny, MY; Mustafa, SM, 2016
)
0.43
"Dexamethasone combined with other antiemetics provided better prophylaxis than single antiemetics against postoperative nausea and vomiting after laparoscopic cholecystectomy."( Dexamethasone combined with other antiemetics versus single antiemetics for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: An updated systematic review and meta-analysis.
Abushouk, AI; Ahmed, H; Al Nahrawi, S; Attia, A; Awad, K; Elsherbeny, MY; Mustafa, SM, 2016
)
0.43
"To assess the efficacy and safety of a sufficient dose of DEX (12 mg on day 1, 8 mg on day 2, 16 mg on days 3 and 4) in combination with intravenous fosaprepitant and granisetron, we prospectively examined patients receiving HEC including cisplatin (≥50 mg/m)."( A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy.
Akashi, K; Ariyama, H; Baba, E; Esaki, T; Hirano, G; Inadomi, K; Ito, M; Kumagai, H; Kusaba, H; Makiyama, A; Makiyama, C; Mitsugi, K; Nio, K; Shibata, Y; Shirakawa, T; Takayoshi, K; Tamura, S; Yamanaka, T, 2018
)
0.48
"These results suggest that a sufficient dose of DEX in combination with fosaprepitant and granisetron is optimal as an antiemetic prophylaxis for Japanese patients receiving HEC."( A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy.
Akashi, K; Ariyama, H; Baba, E; Esaki, T; Hirano, G; Inadomi, K; Ito, M; Kumagai, H; Kusaba, H; Makiyama, A; Makiyama, C; Mitsugi, K; Nio, K; Shibata, Y; Shirakawa, T; Takayoshi, K; Tamura, S; Yamanaka, T, 2018
)
0.48
"Preventive use of OLZ combined with standard triplet therapy had promising activity with manageable safety, suggesting that this combination could be an effective standard treatment option for patients with AUC ≥4 mg/mL/min CBDCA combination therapy."( Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study.
Abe, M; Arai, T; Fujita, Y; Hayasaki, Y; Iihara, H; Kado, N; Mori, M; Morishige, KI; Murase, S; Nakamura, K; Sakurai, M; Shimaoka, R; Shimokawa, M; Suzuki, A; Takenaka, M; Yamamoto, S, 2020
)
0.56
"To investigate whether palonosetron is better than granisetron in preventing chemotherapy-induced nausea and vomiting (CINV) in a three-drug combination with dexamethasone and fosaprepitant (Fos) in patients with breast cancer who are placed on anthracycline and cyclophosphamide (AC-based regimen)."( A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophospham
Aogi, K; Baba, M; Chiba, Y; Fujiwara, K; Hirano, G; Imamura, CK; Imoto, S; Matsumoto, K; Matsuura, K; Miyazaki, C; Naito, Y; Osaki, A; Saeki, T; Sato, K; Takahashi, M; Takano, T; Tamura, K; Tokunaga, S; Yanagihara, K, 2020
)
0.56
"75 mg (day 1) or granisetron 1 mg (day 1) combined with dexamethasone (12 mg at day 1, 8 mg at day 2 and day 3) and Fos 150 mg (day 1) before receiving AC-based regimen in a double-blind study."( A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophospham
Aogi, K; Baba, M; Chiba, Y; Fujiwara, K; Hirano, G; Imamura, CK; Imoto, S; Matsumoto, K; Matsuura, K; Miyazaki, C; Naito, Y; Osaki, A; Saeki, T; Sato, K; Takahashi, M; Takano, T; Tamura, K; Tokunaga, S; Yanagihara, K, 2020
)
0.56
"In combination with dexamethasone and Fos, this study suggests that palonosetron is not better than granisetron in chemo-naive patients with primary breast cancer receiving AC-based regimen."( A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophospham
Aogi, K; Baba, M; Chiba, Y; Fujiwara, K; Hirano, G; Imamura, CK; Imoto, S; Matsumoto, K; Matsuura, K; Miyazaki, C; Naito, Y; Osaki, A; Saeki, T; Sato, K; Takahashi, M; Takano, T; Tamura, K; Tokunaga, S; Yanagihara, K, 2020
)
0.56
" In this study, we aimed to detect, document, and descriptively analyze the potential drug-drug interactions in hospitalized solid tumor's patients in a Middle Eastern referral oncology-hematology University-affiliated hospital."( Potential drug-drug Interactions in hospitalized cancer patients: A report from the Middle-East.
Adib-Majlesi, M; Hajigholami, A; Moghaddas, A; Riechelmann, R; Sabzghabaee, AM, 2021
)
0.62
" The potential drug-drug interactions between chemotherapy and nonchemotherapy drugs were evaluated with Lexi-Interact ver."( Potential drug-drug Interactions in hospitalized cancer patients: A report from the Middle-East.
Adib-Majlesi, M; Hajigholami, A; Moghaddas, A; Riechelmann, R; Sabzghabaee, AM, 2021
)
0.62
" We detected 227 drug-drug interactions with moderate or major severity out of included patients in which 96, 71, 32, and 28 interactions were in the category of C, D, B, and X, respectively."( Potential drug-drug Interactions in hospitalized cancer patients: A report from the Middle-East.
Adib-Majlesi, M; Hajigholami, A; Moghaddas, A; Riechelmann, R; Sabzghabaee, AM, 2021
)
0.62
"Potentially moderate or major drug-drug interactions frequently occur among solid tumor's cancer patients necessitate the establishment of a clinical pharmacy service for providing relevant pharmacotherapy consultations to prevent this potentially serious concern."( Potential drug-drug Interactions in hospitalized cancer patients: A report from the Middle-East.
Adib-Majlesi, M; Hajigholami, A; Moghaddas, A; Riechelmann, R; Sabzghabaee, AM, 2021
)
0.62
" This study aimed to evaluate the antiemetic efficacy of palonosetron (PALO) over granisetron (GRA) in combination with dexamethasone for multiple highly emetogenic chemotherapy drugs (HEC), especially in chemotherapy regimens in Egyptian breast cancer patients and cisplatin-based regimens in other diseases."( Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
A El-Azab, G; A Mahrous, M; A Tawfik, H, 2021
)
0.62
" All patients received dexamethasone in combination with the 5-HT3 receptor antagonist."( Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
A El-Azab, G; A Mahrous, M; A Tawfik, H, 2021
)
0.62
"Palonosetron, combined with dexamethasone, is more effective than granisetron and dexamethasone combination against both acute and delayed emesis induced by highly emetogenic chemotherapy (HEC) cisplatin-based protocols and the combination of cyclophosphamide and anthracyclines (AC)."( Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
A El-Azab, G; A Mahrous, M; A Tawfik, H, 2021
)
0.62
"The authors sought to quantify the clinical impacts of granisetron, ketamine, dexmedetomidine, and lidocaine combined with fentanyl, for procedural sedation and analgesia in cystoscopy and for bladder catheter tolerance."( Efficacy appraisal of four regimens (granisetron, ketamine, dexmedetomidine, and lidocaine combined with fentanyl) for cystoscopy-associated sedation and analgesia and catheter-related bladder tolerance: a randomized clinical trial.
Almasi-Hashiani, A; Jafarirismani, R; Modir, H; Shamaii, K,
)
0.13

Bioavailability

Grisetron hydrochloride (GH) spanlastic in mucoadhesive gels and lyophilized inserts for intranasal administration to improve GH bioavailability and brain targeting. Granisetron was found to be well absorbed through nasal route.

ExcerptReferenceRelevance
" Complete absorption occurred from the gastrointestinal tract following oral dosing, but bioavailability was reduced by first-pass metabolism in all three species."( Metabolism and disposition of 14C-granisetron in rat, dog and man after intravenous and oral dosing.
Austin, NE; Bloomer, JC; Clarke, SE; Haddock, RE; Higham, FC; Hollis, FJ; Nash, M; Shardlow, PC; Tasker, TC; Woods, FR, 1994
)
0.29
" The bioavailability evaluation was based mainly on the area under the curve (AUC) (mean values: 52."( Evaluation of the bioequivalence of tablet and capsule formulations of granisetron in patients undergoing cytotoxic chemotherapy for malignant disease.
Adenis, L; Allen, A; Bessell, E; Bressolle, F; Carmichael, J; Cupissol, D; Romain, D; Wargenau, M, 1993
)
0.29
" The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic, bioavailability or bioequivalence studies."( Quantification of granisetron in human plasma by liquid chromatography coupled to electrospray tandem mass spectrometry.
Boosi, R; Kandikere, VN; Maurya, S; Mudigonda, K; Nirogi, RV; Shukla, M, 2006
)
0.33
" Granisetron was found to be well absorbed through nasal route and the bioavailability of this drug following nasal administration was comparable with that of intravenous administration."( Nasal absorption studies of granisetron in rats using a validated high-performance liquid chromatographic method with mass spectrometric detection.
Woo, JS, 2007
)
0.34
" Granisetron suffers from reduced oral bioavailability (≈60%) due to hepatic metabolism."( Provesicular granisetron hydrochloride buccal formulations: in vitro evaluation and preliminary investigation of in vivo performance.
Ahmed, S; El-Latif Badawi, AA; El-Nabarawi, MA; El-Setouhy, DA, 2014
)
0.4
"Teriparatide delayed the time-radioactivity profile of [(18)F]FDG in blood and significantly reduced its absorption rate constant (k a ), determined from non-compartmental analysis, to 60% of control."( Exploration of Antiemetics for Osteoporosis Therapy-Induced Nausea and Vomiting Using PET Molecular Imaging Analysis to Gastrointestinal Pharmacokinetics.
Cui, Y; Hayashinaka, E; Katayama, Y; Nakaoka, T; Okauchi, T; Onoe, K; Shingaki, T; Takashima, T; Wada, Y; Watanabe, Y, 2016
)
0.43
"5 fold enhancement in bioavailability as compared with drug solution."( Design, Optimization and Characterization of Granisetron HCl Loaded Nano-gel for Transdermal Delivery.
Aggarwal, G; Chaudhary, H; Kumar, V, 2017
)
0.46
"The aim of this study was to formulate granisetron hydrochloride (GH) spanlastic in mucoadhesive gels and lyophilized inserts for intranasal administration to improve GH bioavailability and brain targeting."( Development of novel bioadhesive granisetron hydrochloride spanlastic gel and insert for brain targeting and study their effects on rats.
Abdelmonem, R; Attia, A; El Nabarawi, M, 2018
)
0.48
"In oral bioavailability studies, evaluation of the absorption and transport of drugs and food components across the intestinal barrier is crucial."( Dynamic in vitro intestinal barrier model coupled to chip-based liquid chromatography mass spectrometry for oral bioavailability studies.
Bouwmeester, H; Gerssen, A; Nielen, MWF; Santbergen, MJC; van der Zande, M, 2020
)
0.56
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36

Dosage Studied

Grisetron is a more potent, longer acting and pharmacologically "cleaner" compound with a more conventional dose-response profile. In the trial, the dosage of granisetron tablet was 2 mg once a day.

ExcerptRelevanceReference
" Dosing with granisetron was more simple, with over 85% of patients requiring only a single prophylactic dose."( A single-blind study of the efficacy and safety of intravenous granisetron compared with alizapride plus dexamethasone in the prophylaxis and control of emesis in patients receiving 5-day cytostatic therapy. The Granisetron Study Group.
Bremer, K, 1992
)
0.28
" Our data suggest that in comparison to ondansetron, granisetron is a more potent, longer acting and pharmacologically "cleaner" compound with a more conventional dose-response profile."( Are all 5-HT3 receptor antagonists the same?
Andrews, PL; Bhandari, P; Bingham, S; Blower, PR; Davey, PT; Marr, HE, 1992
)
0.28
"0 mg twice daily is an effective antiemetic, offering a convenient dosing regimen without significant adverse events."( Oral granisetron--simple and effective: a preliminary report. The Granisetron Study Group.
Hacking, A, 1992
)
0.28
") had no effects on duodenal intraluminal pressure, but reduced the responses to distension with a bell-shaped dose-response relationship."( The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distension.
Moss, HE; Sanger, GJ, 1990
)
0.28
" After a 4- to 5-day recovery, piglets were hydrated, then dosed with cisplatin (5."( The piglet as a suitable animal model for studying the delayed phase of cisplatin-induced emesis.
Blower, P; Grélot, L; Milano, S; Romain, D, 1995
)
0.29
" In man, about 60% of dosed radioactivity was excreted in urine and 36% in faeces after both intravenous and oral dosing."( Metabolism and disposition of 14C-granisetron in rat, dog and man after intravenous and oral dosing.
Austin, NE; Bloomer, JC; Clarke, SE; Haddock, RE; Higham, FC; Hollis, FJ; Nash, M; Shardlow, PC; Tasker, TC; Woods, FR, 1994
)
0.29
"This is the first double-blind clinical trial in a homogenous group of patients to compare the recommended dosing schedules of ondansetron and granisetron in the control of prolonged emesis after cyclophosphamide-containing chemotherapy (48% CMF, 35% EC) for breast cancer."( Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Cancer P
Corette, L; Cronje, JD; Froger, X; Goedhals, L; Gudgeon, A; Laplaige, P; McQuade, B; Roberts, JT; Stewart, A; Tubiana-Hulin, M,
)
0.13
" Prospective studies designed to generate comparative clinical and economic data are needed in which outcomes are assessed by a common scale and in which previously established optimal doses and dosing schedules of each compound (either alone or in combination therapy) are used."( Impact of ondansetron and granisetron on chemotherapy-induced emesis in adults: the need for comparative pharmacoeconomic data.
Hedayati, S; Moatti, JP; Seitz, JF,
)
0.13
"0001), and fewer patients were administered additional antiemetic medication in the 10-micrograms/kg dosing groups than in the 5-micrograms/kg dosing group."( Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.
Fitts, D; Gralla, RJ; Grunberg, SM; Kaplan, HG; Navari, RM; Palmer, R, 1994
)
0.29
"kg-1 is considered to be the appropriate dosage for preventing postoperative emesis after anaesthesia."( Optimal anti-emetic dose of granisetron for preventing postoperative nausea and vomiting.
Fujii, Y; Tanaka, H; Toyooka, H, 1994
)
0.29
" Thus, an efficient anti-emetic drug with less frequent dosing, using a simplified dosage regimen and producing a reduction in anticipatory nausea and vomiting and in nursing time, may result in an overall reduction in cost."( Clinical studies to assess the economic impact of new therapies: pragmatic approaches to measuring costs.
Kirchner, V, 1993
)
0.29
" In addition it offered a simple and convenient dosing regimen and a safer side-effect profile."( The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. The Granisetron Study Group.
, 1993
)
0.29
" From these results, single administration of oral granisetron at a dose of 2 mg once a day was considered to be the optimal administration and dosage for nausea and vomiting induced by the administration of anticancer drugs."( [Clinical evaluation of granisetron for nausea and vomiting induced by anticancer drugs--optimal dose-finding study].
Furue, H; Niitani, H; Ogawa, N; Ohta, K; Suminaga, M; Taguchi, T, 1993
)
0.29
" In the trial, the dosage of granisetron tablet was 2 mg once a day, and the drug was given before each chemotherapy for 6 consecutive days."( [Study on the inhibitory effect of oral granisetron against nausea/vomiting induced by cytosine arabinoside containing chemotherapy for tumors in the hematopoietic organs].
Gondo, H; Harada, M; Matsuishi, H; Omori, F; Otsuka, T; Shibuya, T; Taniguchi, S; Teshima, T; Yamano, Y; Yamazaki, K, 1993
)
0.29
" They were invited to return data on patient demography, chemotherapy duration, granisetron dosing and adverse experiences."( Granisetron (Kytril): a survey of use in clinical practice in Switzerland.
Casey, PA; Terrey, JP, 1995
)
0.29
" These experimental conditions are also suitable for analysis of the considered compounds in pharmaceutical dosage forms or in biological fluids."( Retention behaviour of anti-emetic serotonin antagonists in reversed phase high performance liquid chromatography.
Barbato, F; La Rotonda, MI; Quaglia, F, 1995
)
0.29
" We determined the dose-response relation of granisetron and the financial impact of using this drug in preventing PONV after pediatric outpatient surgery."( The dose-response relation and cost-effectiveness of granisetron for the prophylaxis of pediatric postoperative emesis.
Cieslak, GD; Pennant, JH; Phillips, MB; Watcha, MF, 1996
)
0.29
"6% acetic acid) in conscious rats with a bell-shaped dose-response curve."( Response heterogeneity of 5-HT3 receptor antagonists in a rat visceral hypersensitivity model.
Dahl, SG; Junien, JL; Langlois, A; Pascaud, X; Rivière, PJ, 1996
)
0.29
" Granisetron also remained more cost effective than ondansetron with variations in the antiemetic dosage regimens, except when the granisetron dosage remained unchanged while the ondansetron dosage was reduced to a single 8mg intravenous dose on each day prior to chemotherapy (and no change in efficacy was assumed)."( Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.
Benfield, P; Plosker, GL, 1996
)
0.29
", but without changing the maximum response or the bell-shaped nature of the dose-response curve for granisetron."( 5-HT4 receptor antagonism potentiates inhibition of intestinal allodynia by 5-HT3 receptor antagonism in conscious rats.
Banner, SE; Sanger, GJ; Smith, MI, 1999
)
0.3
" Both dosage forms were well tolerated."( Efficacy and safety of oral granisetron versus i.v. granisetron in patients undergoing peripheral blood progenitor cell and bone marrow transplantation.
Abang, AM; Carter, TH; Mandanas, RA; Pham, T; Roy, V; Selby, GB; Takemoto, MH, 2000
)
0.31
" The, pharmacokinetics of GRN has not been fully evaluated in such patients, however, and its dosage regimen is still controversial."( Pharmacokinetics of granisetron in adults and children with malignant diseases.
Hirano, K; Honma, T; Mino, K; Nakabayashi, T; Saitoh, H; Sato, M; Takada, M; Takeda, T; Wada, I, 2001
)
0.31
" Toxicity management consisted of dosage reduction or treatment delay; treatment often was discontinued."( Pegylated liposomal doxorubicin: tolerability and toxicity.
Goram, AL; Richmond, PL, 2001
)
0.31
"We performed a meta-analysis on granisetron in the prevention of postoperative nausea and vomiting (PONV) and further investigated whether total results and the dose-response characteristics may be significantly affected by a single centre."( The influence of a dominating centre on a quantitative systematic review of granisetron for preventing postoperative nausea and vomiting.
Apfel, CC; Eberhart, LH; Georgieff, M; Kranke, P; Roewer, N, 2001
)
0.31
"Overall results and dose-response characteristics of meta-analyses may be significantly altered by one dominating centre."( The influence of a dominating centre on a quantitative systematic review of granisetron for preventing postoperative nausea and vomiting.
Apfel, CC; Eberhart, LH; Georgieff, M; Kranke, P; Roewer, N, 2001
)
0.31
" Patient preference for the dosage form was also investigated."( [Evaluation of efficacy of ramosetron orally disintegrating tablets and patient preference as to the dosage form in gynecological cancer chemotherapy].
Nakayama, S; Noda, T; Torii, Y, 2001
)
0.31
" The aim of this article is to examine the hypothesis that there is a dose-response effect of granisetron for preventing chemotherapy-induced nausea and vomiting in cancer patients."( Granisetron: is there a dose-response effect on nausea and vomiting?
Minami, M, 2003
)
0.32
" Subsequently, patients had the option of the alternative dosing regimen or to return to conventional antiemetic therapy."( High-dose i.v. granisetron for the prevention of chemotherapy-induced emesis: cardiac safety and tolerability.
Carmichael, J; Harris, AL, 2003
)
0.32
" Furthermore, in the 7 days following dosing there were no serious adverse events leading to withdrawal from the trial."( The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy.
Carmichael, J; Harris, AL, 2004
)
0.32
" Subjects (n = 12; 18-60 years) received granisetron (40 microg kg(-1)) infused over 3 min, six days before and on the eighth day of dosing with cimetidine (200 mg, four times a day)."( The effect of repeat dosing with cimetidine on the pharmacokinetics of intravenous granisetron in healthy volunteers.
Youlten, L, 2004
)
0.32
"15 mg/kg followed by 1 dose of the same dosage orally."( Single-dose oral granisetron versus multidose intravenous ondansetron for moderately emetogenic cyclophosphamide-based chemotherapy in pediatric outpatients with acute lymphoblastic leukemia.
Hu, WY; Hung, IJ; Jaing, TH; Tsay, PK; Yang, CP,
)
0.13
" In this study, the authors explore the dose-response relationship between granisetron administered just prior to the end of surgery and post-operative nausea and vomiting in patients undergoing abdominal hysterectomy."( A randomized, double-blind, close-ranging, pilot study of intravenous granisetron in the prevention of postoperative nausea and vomiting in patients abdominal hysterectomy.
Coop, A; D'Angelo, R; Dalby, P; Doblar, D; Gan, TJ; Hantler, C; Kovac, A; Melson, T; Minkowitz, H; Philip, B, 2005
)
0.33
" This pilot study did not identify a dose-response relationship."( A randomized, double-blind, close-ranging, pilot study of intravenous granisetron in the prevention of postoperative nausea and vomiting in patients abdominal hysterectomy.
Coop, A; D'Angelo, R; Dalby, P; Doblar, D; Gan, TJ; Hantler, C; Kovac, A; Melson, T; Minkowitz, H; Philip, B, 2005
)
0.33
" Some differences were noted in dosing subanalyses."( A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis.
Arnold, D; Grothey, A; Hinke, A; Jordan, K; Schmoll, HJ; Voigt, W; Wolf, HH, 2007
)
0.34
"Unlike patients with chemotherapy-induced nausea and vomiting, perioperative patients who failed ondansetron prophylaxis did not have a significant response to cross-over dosing with granisetron."( Granisetron versus ondansetron treatment for breakthrough postoperative nausea and vomiting after prophylactic ondansetron failure: a pilot study.
Arheart, KL; Birnbach, DJ; Candiotti, KA; Deepika, K; Kamat, A; Lubarsky, DA; Nhuch, F, 2007
)
0.34
" Although forms of the drug are commercially available for intravenous and oral dosage, there is a need for intranasal delivery formulations in specific patient populations in which the use of these dosage forms may be unfeasible and/or inconvenient."( Nasal absorption studies of granisetron in rats using a validated high-performance liquid chromatographic method with mass spectrometric detection.
Woo, JS, 2007
)
0.34
" Given the recommended dosage in the guidelines and the economic need for reduction of medical care expenses in Japan, prophylactic administration of GRN at 1 mg may be an appropriate, alternative treatment for acute CINV in cancer patients."( Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trial.
Fujiwara, Y; Hashimoto, H; Hojo, T; Kaneko, M; Kato, Y; Katsumata, N; Kobayashi, Y; Satake, S; Takashima, A; Takeuchi, M; Yamamoto, H; Yonemura, M, 2009
)
0.35
" The true efficacy of granisetron in gagger patients with this treatment protocol has yet to be fully established, although it has been theorized that an increased dosage of granisetron may have a better effect."( Does granisetron eliminate the gag reflex? A crossover, double-blind, placebo-controlled pilot study.
Barenboim, SF; Dvoyris, V; Kaufman, E, 2009
)
0.35
" The temporal and dose-response relationships suggested a possible association between the depressive symptoms and corticosteroid."( Suicide associated with corticosteroid use during chemotherapy: case report.
Kinoshita, H; Matsumoto, Y; Shimizu, C; Shimizu, K; Uchitomi, Y, 2010
)
0.36
" Therefore, the nanoemulsion system developed in this study offers a promising vehicle for the transdermal delivery system of granisetron hydrochloride, which may be as effective as oral or intravenous dosage forms and avoid some difficulties associated with these dosage forms."( Preparation and the in vitro evaluation of nanoemulsion system for the transdermal delivery of granisetron hydrochloride.
Wei, YM; Xiao, SH; Ye, Y; Zhao, L; Zheng, WW, 2010
)
0.36
" The drug is available in tablet dosage form and parenteral dosage form containing benzyl alcohol as a preservative."( First derivative spectrophotometric determination of granisetron hydrochloride in presence of its hydrolytic products and preservative and application to pharmaceutical preparations.
Bedair, MM; Hewala, II; Shousha, SM, 2013
)
0.39
"As part of our efforts to further modify the physicochemical properties of this market drug, with the ultimate goal to formulate a better dosage form for GRN, this work was carried out to improve its permeability in vitro."( In vitro percutaneous absorption enhancement of granisetron by chemical penetration enhancers.
Cun, D; Fang, L; Li, L; Li, W; Ma, X; Sun, L; Xi, H; Zhao, N, 2013
)
0.39
" The prepared provesicular buccoadhesive tablet of granisetron (F19) might help bypass hepatic first-pass metabolism and improve bioavailability of granisetron with the possibility of reducing reported daily dose (2mg) and reducing dosing frequency."( Provesicular granisetron hydrochloride buccal formulations: in vitro evaluation and preliminary investigation of in vivo performance.
Ahmed, S; El-Latif Badawi, AA; El-Nabarawi, MA; El-Setouhy, DA, 2014
)
0.4
" Finally, the proposed method could be successfully utilized for estimation of granisetron HCl and its related substances in tablets and parenteral dosage forms, as well as for monitoring degradation under various stress conditions."( Hydrophilic interaction liquid chromatography in analysis of granisetron HCl and its related substances. Retention mechanisms and method development.
Jančić-Stojanović, B; Jovanović, M; Maksić, J; Rakić, T; Stajić, A; Tumpa, A, 2016
)
0.43
"045), with the cumulative intraoperative dosage also increased in the granisetron group (P=0."( Granisetron reduces the need for uterotonics but not sympathomimetics during cesarean delivery.
Baldauf, HP; Fischer, D; Jennewein, L; Louwen, F; Raimann, FJ; Weber, CF; Zacharowski, K, 2019
)
0.51
" Briefly, minks were fasted one day before experiment and given DAS by intraperitoneally and orally dosing on the experiment day."( Type A Trichothecene Diacetoxyscirpenol-Induced Emesis Corresponds to Secretion of Peptide YY and Serotonin in Mink.
Kuca, K; Nepovimova, E; Wu, Q; Wu, W, 2020
)
0.56
" However, a U-shaped dose-response curve obtained with certain parameters may limit the therapeutic potential of this strategy and require further investigation."( Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat.
Bédard, D; Frouni, I; Hamadjida, A; Huot, P; Kwan, C, 2021
)
0.62
" In A549 cells, granisetron 7-hydroxylation showed a better dose-response from 0 to 10000 nM FICZ treatment than EROD."( LC-MS-based assay of granisetron 7-hydroxylation activity for the evaluation of CYP1A1 induction from diesel particulate matter-exposed hepatic and respiratory cell lines.
Baik, S; Cho, H; Choi, I; Kim, SK; Ryu, CS, 2022
)
0.72
" The sufentanil 5 µg/kg dosage in the PCA regimen is superior to sufentanil 4 µg/kg alone or combined with tramadol in lowering moderate to severe pain."( Effectiveness of Sufentanil-Based Patient-Controlled Analgesia Regimen in Children and Incidence of Adverse Events Following Major Congenital Structure Repairs.
Liu, F; Xie, D; Zuo, Y, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
aromatic amideAn amide in which the amide linkage is bonded directly to an aromatic system.
indazoles
indazoles
aromatic amideAn amide in which the amide linkage is bonded directly to an aromatic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (37)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency25.11890.009610.525035.4813AID1479145
thioredoxin reductaseRattus norvegicus (Norway rat)Potency35.48130.100020.879379.4328AID588456
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency39.81070.035520.977089.1251AID504332
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency8.49210.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 3EHomo sapiens (human)Ki0.01670.00100.88359.9000AID5980; AID6344
Solute carrier family 22 member 2Homo sapiens (human)IC50 (µMol)4.30000.40003.10009.7000AID721751
5-hydroxytryptamine receptor 3ACavia porcellus (domestic guinea pig)Ki0.00400.00100.03000.0851AID1889692
5-hydroxytryptamine receptor 3BHomo sapiens (human)Ki0.01670.00100.87119.9000AID5980; AID6344
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Ki1.00000.00020.667710.0000AID4765; AID5290
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Ki38.00000.00000.12345.5000AID146640
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki1.00000.00010.601710.0000AID5290
Neuronal acetylcholine receptor subunit beta-2Homo sapiens (human)Ki38.00000.00000.11173.5400AID146640
DRattus norvegicus (Norway rat)IC50 (µMol)3.80190.00030.50267.7625AID243189
DRattus norvegicus (Norway rat)Ki0.00910.00010.610010.0000AID6285
D(3) dopamine receptorRattus norvegicus (Norway rat)Ki0.00910.00010.25675.8000AID6285
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki1.00000.00010.739610.0000AID4328
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)3.80190.00031.09147.7625AID243189
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)3.80190.00031.09147.7625AID243189
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)3.80190.00031.06917.7625AID243189
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)IC50 (µMol)3.80190.00070.97749.7000AID243189
B2 bradykinin receptorRattus norvegicus (Norway rat)Ki1.00000.00010.00030.0005AID4328
D(1B) dopamine receptorRattus norvegicus (Norway rat)Ki0.00910.00020.24622.0000AID6285
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Ki1.00000.00031.29679.2440AID4702
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)Ki1.00000.00101.67479.2000AID4875
D(4) dopamine receptorRattus norvegicus (Norway rat)Ki0.00910.00020.18872.0000AID6285
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Ki1.00000.00020.590910.0000AID5290
Neuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)Ki67.00000.00000.65225.4000AID145991
5-hydroxytryptamine receptor 3ARattus norvegicus (Norway rat)IC50 (µMol)1.76000.00021.13514.6000AID6058
5-hydroxytryptamine receptor 3ARattus norvegicus (Norway rat)Ki1.05130.00020.484110.0000AID239587; AID5881; AID5882; AID5883; AID5886; AID5887; AID5890; AID5893; AID5896; AID5898; AID6132; AID6136; AID6137; AID6284; AID6285; AID6292; AID6298
Neuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)Ki38.00000.00000.11573.5400AID146640
5-hydroxytryptamine receptor 3AHomo sapiens (human)Ki0.00950.00000.74119.9000AID461556; AID537659; AID5980; AID6344; AID643471
Neuronal acetylcholine receptor subunit alpha-7Mus musculus (house mouse)Ki10.00000.00120.12230.4800AID146789
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)1.00000.00010.54948.4000AID61534
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.00620.00000.437510.0000AID6137; AID6285
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)3.77020.00091.901410.0000AID243151; AID243189; AID420668; AID576612; AID82355
5-hydroxytryptamine receptor 3DHomo sapiens (human)Ki0.01670.00100.88359.9000AID5980; AID6344
Multidrug and toxin extrusion protein 2Homo sapiens (human)IC50 (µMol)311.00000.16003.95718.6000AID721752
5-hydroxytryptamine receptor 3CHomo sapiens (human)Ki0.01670.00100.88359.9000AID5980; AID6344
Multidrug and toxin extrusion protein 1Homo sapiens (human)IC50 (µMol)5.00000.01002.765610.0000AID721754
5-hydroxytryptamine receptor 3BRattus norvegicus (Norway rat)IC50 (µMol)1.76000.00041.17424.6000AID6058
5-hydroxytryptamine receptor 3BRattus norvegicus (Norway rat)Ki1.05130.00020.502310.0000AID239587; AID5881; AID5882; AID5883; AID5886; AID5887; AID5890; AID5893; AID5896; AID5898; AID6132; AID6136; AID6137; AID6284; AID6285; AID6292; AID6298
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 3EHomo sapiens (human)Kd0.00010.00000.02840.1060AID6026; AID6027
5-hydroxytryptamine receptor 3BHomo sapiens (human)EC50 (µMol)0.50000.00101.10032.8000AID1056959
5-hydroxytryptamine receptor 3BHomo sapiens (human)Kd0.00020.00000.01370.1060AID1056974; AID1056975; AID1056976; AID1056977; AID1056978; AID1056990; AID6026; AID6027
5-hydroxytryptamine receptor 3AHomo sapiens (human)EC50 (µMol)0.21960.00100.65503.8000AID1056959; AID1056961; AID1056962; AID1056963; AID1056964; AID1056966; AID1056968; AID1056969; AID1056970; AID1056971
5-hydroxytryptamine receptor 3AHomo sapiens (human)Kd0.00040.00000.00980.1060AID1056978; AID1056980; AID1056981; AID1056982; AID1056983; AID1056984; AID1056985; AID1056987; AID1056988; AID1056989; AID1056991; AID6026; AID6027
5-hydroxytryptamine receptor 3DHomo sapiens (human)Kd0.00010.00000.02840.1060AID6026; AID6027
5-hydroxytryptamine receptor 3CHomo sapiens (human)Kd0.00010.00000.02840.1060AID6026; AID6027
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 3EHomo sapiens (human)Kb0.01290.00930.01390.0194AID5963
5-hydroxytryptamine receptor 3BHomo sapiens (human)Kb0.01290.00930.01390.0194AID5963
5-hydroxytryptamine receptor 3AHomo sapiens (human)Kb0.01290.00930.01390.0194AID5963
5-hydroxytryptamine receptor 3DHomo sapiens (human)Kb0.01290.00930.01390.0194AID5963
5-hydroxytryptamine receptor 3CHomo sapiens (human)Kb0.01290.00930.01390.0194AID5963
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (113)

Processvia Protein(s)Taxonomy
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3EHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3EHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3EHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3EHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3EHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3EHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processSolute carrier family 22 member 2Homo sapiens (human)
positive regulation of gene expressionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
monoatomic cation transportSolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin transportSolute carrier family 22 member 2Homo sapiens (human)
body fluid secretionSolute carrier family 22 member 2Homo sapiens (human)
organic cation transportSolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 2Homo sapiens (human)
amine transportSolute carrier family 22 member 2Homo sapiens (human)
putrescine transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transportSolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 2Homo sapiens (human)
choline transportSolute carrier family 22 member 2Homo sapiens (human)
dopamine transportSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 2Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 2Homo sapiens (human)
histamine transportSolute carrier family 22 member 2Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 2Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
amino acid import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 2Homo sapiens (human)
L-arginine import across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
export across plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
L-alpha-amino acid transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transportSolute carrier family 22 member 2Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 2Homo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3BHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3BHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3BHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3BHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3BHomo sapiens (human)
response to hypoxiaNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
monoatomic ion transportNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
calcium ion transportNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
smooth muscle contractionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
signal transductionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
synaptic transmission, cholinergicNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
visual perceptionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
sensory perception of soundNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
learningNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
memoryNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
locomotory behaviorNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
associative learningNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
visual learningNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of dopamine secretionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
sensory perception of painNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
vestibulocochlear nerve developmentNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
optic nerve morphogenesisNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
lateral geniculate nucleus developmentNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
central nervous system projection neuron axonogenesisNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
positive regulation of B cell proliferationNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of synaptic transmission, dopaminergicNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
positive regulation of dopamine secretionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
monoatomic ion transmembrane transportNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
response to nicotineNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
behavioral response to nicotineNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
social behaviorNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of dopamine metabolic processNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
B cell activationNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
response to cocaineNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of circadian sleep/wake cycle, REM sleepNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
response to ethanolNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
negative regulation of action potentialNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of dendrite morphogenesisNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
nervous system processNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
cognitionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
membrane depolarizationNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of synapse assemblyNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
synaptic transmission involved in micturitionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine receptor signaling pathwayNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
response to acetylcholineNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
chemical synaptic transmissionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
monoatomic ion transportNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
regulation of smooth muscle contractionNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
signal transductionNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activityNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
synaptic transmission, cholinergicNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
nervous system developmentNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
locomotory behaviorNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
regulation of acetylcholine secretion, neurotransmissionNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
monoatomic ion transmembrane transportNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
behavioral response to nicotineNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
regulation of membrane potentialNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
regulation of dendrite morphogenesisNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
synaptic transmission involved in micturitionNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
acetylcholine receptor signaling pathwayNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
response to acetylcholineNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
response to nicotineNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
membrane depolarizationNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
action potentialNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
response to hypoxiaNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
DNA repairNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
monoatomic ion transportNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
calcium ion transportNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
response to oxidative stressNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
signal transductionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
chemical synaptic transmissionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
synaptic transmission, cholinergicNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
regulation of dopamine secretionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
sensory perception of painNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
monoatomic ion transmembrane transportNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
response to nicotineNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
behavioral response to nicotineNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
B cell activationNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
regulation of membrane potentialNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
nervous system processNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
cognitionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
membrane depolarizationNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
inhibitory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine receptor signaling pathwayNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3AHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3DHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3DHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3DHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3DHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3DHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3DHomo sapiens (human)
organic cation transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
transmembrane transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
proton transmembrane transportMultidrug and toxin extrusion protein 2Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3CHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3CHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3CHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3CHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3CHomo sapiens (human)
xenobiotic transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
amino acid import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine import across plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-alpha-amino acid transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
proton transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transportMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (45)

Processvia Protein(s)Taxonomy
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3EHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3EHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3EHomo sapiens (human)
amine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
acetylcholine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-amino acid transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
choline transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
efflux transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
L-arginine transmembrane transporter activitySolute carrier family 22 member 2Homo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3BHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3BHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3BHomo sapiens (human)
protein bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
ligand-gated monoatomic ion channel activityNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine receptor activityNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
protein-containing complex bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
quaternary ammonium group bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
heterocyclic compound bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
protein bindingNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
ligand-gated monoatomic ion channel activityNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
acetylcholine receptor activityNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
acetylcholine bindingNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
protein bindingNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
ligand-gated monoatomic ion channel activityNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine receptor activityNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine bindingNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 3DHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3DHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3DHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3DHomo sapiens (human)
organic cation transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
antiporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
polyspecific organic cation:proton antiporter activityMultidrug and toxin extrusion protein 2Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 3CHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3CHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3CHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3CHomo sapiens (human)
protein bindingMultidrug and toxin extrusion protein 1Homo sapiens (human)
organic cation transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-amino acid transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
thiamine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
putrescine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
L-arginine transmembrane transporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
polyspecific organic cation:proton antiporter activityMultidrug and toxin extrusion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (30)

Processvia Protein(s)Taxonomy
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membrane5-hydroxytryptamine receptor 3EHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3EHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3EHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3EHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3EHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3EHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3EHomo sapiens (human)
plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
membraneSolute carrier family 22 member 2Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 2Homo sapiens (human)
presynapseSolute carrier family 22 member 2Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3BHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3BHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3BHomo sapiens (human)
cell surface5-hydroxytryptamine receptor 3BHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3BHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3BHomo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
external side of plasma membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
presynaptic membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
plasma membrane raftNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
cholinergic synapseNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
postsynaptic specialization membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine-gated channel complexNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
neuron projectionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
synapseNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
endoplasmic reticulumNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
Golgi apparatusNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
postsynaptic densityNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
membraneNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
nuclear speckNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
dendriteNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
neuronal cell bodyNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
plasma membrane raftNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
postsynaptic membraneNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
acetylcholine-gated channel complexNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
neuron projectionNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
synapseNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
external side of plasma membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
dendriteNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
neuronal cell bodyNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
postsynaptic membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine-gated channel complexNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
synapseNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
neuron projectionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
cleavage furrow5-hydroxytryptamine receptor 3AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3AHomo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3DHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3DHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3DHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3DHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3DHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3DHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3DHomo sapiens (human)
plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
apical plasma membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
membraneMultidrug and toxin extrusion protein 2Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3CHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3CHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3CHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3CHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3CHomo sapiens (human)
plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
basolateral plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
apical plasma membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
membraneMultidrug and toxin extrusion protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (229)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1409465Reduction in viability of human PC3 cells after 6 hrs by fluorescence assay2018Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21
Pathway-Based Drug Repositioning for Cancers: Computational Prediction and Experimental Validation.
AID1409464Reduction in viability of human AsPC1 cells after 6 hrs by fluorescence assay2018Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21
Pathway-Based Drug Repositioning for Cancers: Computational Prediction and Experimental Validation.
AID1409461Reduction in viability of human HET-1A cells after 6 hrs by fluorescence assay2018Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21
Pathway-Based Drug Repositioning for Cancers: Computational Prediction and Experimental Validation.
AID1409462Reduction in viability of human A549 cells after 6 hrs by fluorescence assay2018Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21
Pathway-Based Drug Repositioning for Cancers: Computational Prediction and Experimental Validation.
AID1409463Reduction in viability of human Caco2 cells after 6 hrs by fluorescence assay2018Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21
Pathway-Based Drug Repositioning for Cancers: Computational Prediction and Experimental Validation.
AID1056962Agonist activity at human 5-HT3A receptor D165A mutant by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID178575Effective dose required to reduce von benzold jarisch reflex response to 5-HT was determined; Value ranges from 10-30 ug/Kg1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Synthesis and biochemical evaluation of tritium-labeled 1-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxa mide, a useful radioligand for 5HT3 receptors.
AID5963Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay1997Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21
Phenylimidazolidin-2-one derivatives as selective 5-HT3 receptor antagonists and refinement of the pharmacophore model for 5-HT3 receptor binding.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID143665Quantitative effect on the [14C]guanidinium accumulation in NG 108-15 cells.1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.
AID185962Percentage inhibition von benzold jarisch reflex in rats when the compound was administered at dose of 100 ug/Kg 1 hr postadministration1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Synthesis and biochemical evaluation of tritium-labeled 1-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxa mide, a useful radioligand for 5HT3 receptors.
AID6026Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1056970Agonist activity at human wild type 5-HT3A receptor expressed in HEK293 cells by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID1056989Binding affinity to human 5-HT3A receptor Y73A mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID5896In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex1997Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21
Phenylimidazolidin-2-one derivatives as selective 5-HT3 receptor antagonists and refinement of the pharmacophore model for 5-HT3 receptor binding.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID6255Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
Synthesis and structure-activity relationships of potent and orally active 5-HT4 receptor antagonists: indazole and benzimidazolone derivatives.
AID6129Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.
AID5887Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Development of high-affinity 5-HT3 receptor antagonists. Structure-affinity relationships of novel 1,7-annelated indole derivatives.
AID1056975Binding affinity to human 5-HT3B receptor F130A mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID295454Antagonist activity at 5HT3 receptor in Hartley guinea-pig ileum assessed as effect on 5-hydroxytryptamine-induced muscle contraction2007Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10
Regulatory molecules for the 5-HT3 receptor ion channel gating system.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID5890Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. 1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
5-HT3 receptor antagonists. 1. New quinoline derivatives.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID180191The compound was evaluated for the inhibition of the von Bezold-Jarisch reflex in rat administered orally1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Indazoles as indole bioisosteres: synthesis and evaluation of the tropanyl ester and amide of indazole-3-carboxylate as antagonists at the serotonin 5HT3 receptor.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID243189Inhibition of partially open human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel)2005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
A two-state homology model of the hERG K+ channel: application to ligand binding.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID6089Inhibition of 5-HT evoked reflex bradycardia in rat.1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
5-Hydroxytryptamine (5-HT3) receptor antagonists. 1. Indazole and indolizine-3-carboxylic acid derivatives.
AID1056971Agonist activity at human 5-HT3A receptor Y73A mutant by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID5910Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Development of high-affinity 5-HT3 receptor antagonists. 2. Two novel tricyclic benzamides.
AID180190The compound was evaluated for the inhibition of the von Bezold-Jarisch reflex in rat administered intravenously1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Indazoles as indole bioisosteres: synthesis and evaluation of the tropanyl ester and amide of indazole-3-carboxylate as antagonists at the serotonin 5HT3 receptor.
AID5898Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Synthesis and biochemical evaluation of tritium-labeled 1-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxa mide, a useful radioligand for 5HT3 receptors.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID14399Biodistribution in rat cerebellum, expressed as percent I.D./g tissue1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors.
AID229404Selectivity ratio of peroral vs intravenous delivery1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Indazoles as indole bioisosteres: synthesis and evaluation of the tropanyl ester and amide of indazole-3-carboxylate as antagonists at the serotonin 5HT3 receptor.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID5881Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
5-Hydroxytryptamine (5-HT3) receptor antagonists. 1. Indazole and indolizine-3-carboxylic acid derivatives.
AID643471Displacement of [3H]granisetron from human 5HT3A expressed in HEK293 cells after 1 hr by scintillation counting2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
High-affinity fluorescent ligands for the 5-HT(3) receptor.
AID122491Transition time (time required to evacuate the glass bead) in the distal colon in mice at dose 3 mg/kg1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
Benzoxazole derivatives as novel 5-HT3 receptor partial agonists in the gut.
AID6011Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site.
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID5976Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Benzimidazole derivatives. 2. Synthesis and structure-activity relationships of new azabicyclic benzimidazole-4-carboxylic acid derivatives with affinity for serotoninergic 5-HT(3) receptors.
AID721754Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1056967Agonist activity at human 5-HT3A receptor W90C mutant by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056979Binding affinity to human 5-HT3A receptor W183C mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID537660Chemical stability of the compound assessed as half life2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Computational analysis of ligand recognition sites of homo- and heteropentameric 5-HT3 receptors.
AID243151Inhibitory concentration against potassium channel HERG2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
AID14401Biodistribution in rat thalamus, expressed as percent I.D./g tissue1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors.
AID295455Intrinsic activity at 5HT3 receptor in Hartley guinea-pig ileum assessed as muscle contraction at 0.1 mM relative to 5-hydroxytryptamine2007Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10
Regulatory molecules for the 5-HT3 receptor ion channel gating system.
AID6244In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Benzimidazole derivatives. 2. Synthesis and structure-activity relationships of new azabicyclic benzimidazole-4-carboxylic acid derivatives with affinity for serotoninergic 5-HT(3) receptors.
AID1056986Binding affinity to human 5-HT3A receptor W90C mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID183114Inhibitory dose against 5-HT-Evoked Bezold-Jarisch (B-J) reflex in rats1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
Benzoxazole derivatives as novel 5-HT3 receptor partial agonists in the gut.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1056956Agonist activity at human 5-HT3B receptor F130A mutant by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID5884Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Benzimidazole derivatives. 2. Synthesis and structure-activity relationships of new azabicyclic benzimidazole-4-carboxylic acid derivatives with affinity for serotoninergic 5-HT(3) receptors.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1056974Binding affinity to human 5-HT3B receptor Y143A mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID552110Partial agonist activity at human 5HT3A receptor expressed in HEK293 cells at 3 uM relative to 5HT2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.
AID5980Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-151993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
5-HT3 receptor antagonists. 3. Quinoline derivatives which may be effective in the therapy of irritable bowel syndrome.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1222793Dissociation constant, pKa of the compound2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Which metabolites circulate?
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID6056In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration1993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
5-HT3 receptor antagonists. 2. 4-Hydroxy-3-quinolinecarboxylic acid derivatives.
AID6159Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated2002Bioorganic & medicinal chemistry letters, Jan-21, Volume: 12, Issue:2
Synthesis and pharmacology of isoquinuclidine derivatives as 5-HT(3) ligands.
AID4765Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Synthesis and biochemical evaluation of tritium-labeled 1-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxa mide, a useful radioligand for 5HT3 receptors.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1056954Agonist activity at human 5-HT3B receptor E170A mutant by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056958Agonist activity at human 5-HT3B receptor H73A mutant by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID295453Agonist activity at 5HT3 receptor in Hartley guinea-pig ileum assessed as muscle contraction2007Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10
Regulatory molecules for the 5-HT3 receptor ion channel gating system.
AID183155Antagonist activity (100 mg/Kg) for the Bezold Jarisch reflex evoked by 30(mg/Kg) of 5-HT in ethylurethane anesthetized rats (i.v.)1997Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21
Phenylimidazolidin-2-one derivatives as selective 5-HT3 receptor antagonists and refinement of the pharmacophore model for 5-HT3 receptor binding.
AID721753Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID5882Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-656301990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
5-Hydroxytryptamine (5-HT3) receptor antagonists. 1. Indazole and indolizine-3-carboxylic acid derivatives.
AID1056991Binding affinity to human wild type 5-HT3A receptor expressed in HEK293 cells after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID6310Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists.
AID1056965Agonist activity at human 5-HT3A receptor F130Y mutant by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID373867Hepatic clearance in human hepatocytes in absence of fetal calf serum2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
AID1056972Ratio of Kd for human 5-HT3B receptor F130A mutant to Kd for human wild type 5-HT3A/5-HT3B receptor2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID112440Inhibitory activity against 5-HT evoked diarrhea in mice, sc1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
Benzoxazole derivatives as novel 5-HT3 receptor partial agonists in the gut.
AID1056973Binding affinity to human 5-HT3B receptor E170A mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056980Binding affinity to human 5-HT3A receptor D165K mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID183143Potency to inhibit bradycardiac effect measured by Von Bezold-Jarisch assay in 11 anesthetized rats1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists.
AID1056987Binding affinity to human 5-HT3A receptor Y73S mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056966Agonist activity at human 5-HT3A receptor F130A mutant by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID6344In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID461556Displacement of [3H]granisetron from human 5HT3A receptor expressed in HEK293 cells by scintillation counting2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Toward biophysical probes for the 5-HT3 receptor: structure-activity relationship study of granisetron derivatives.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID6284Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID179597Inhibition of the Bezold Jarisch reflex evoked by 30 ug/Kg of 5-HT.1997Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21
Phenylimidazolidin-2-one derivatives as selective 5-HT3 receptor antagonists and refinement of the pharmacophore model for 5-HT3 receptor binding.
AID552297Partial agonist activity at human 5HT3A receptor expressed in HEK293 cells assessed as decrease in 100 uM 5-chloroindole-induced increase in intracellular calcium release at 3 uM relative to 5-HT2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.
AID420669Lipophilicity, log D at pH 7.02009European journal of medicinal chemistry, May, Volume: 44, Issue:5
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID5886Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides.
AID5883Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
5-Hydroxytryptamine (5-HT3) receptor antagonists. 1. Indazole and indolizine-3-carboxylic acid derivatives.
AID72060Antiemetic potency was tested against cisplatin-induced emetic episodes in ferret after oral administration1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Development of high-affinity 5-HT3 receptor antagonists. 2. Two novel tricyclic benzamides.
AID6058Binding affinity towards 5-HT3 receptor in rat was evaluated2002Bioorganic & medicinal chemistry letters, Jan-21, Volume: 12, Issue:2
Synthesis and pharmacology of isoquinuclidine derivatives as 5-HT(3) ligands.
AID72053Antiemetic potency against cisplatin-induced emetic latency period in ferret after intravenous administration1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Development of high-affinity 5-HT3 receptor antagonists. 2. Two novel tricyclic benzamides.
AID145991In vitro Binding affinity towards alpha-3 (PC12) nAChR was determined2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist.
AID1056953Agonist activity at human 5-HT3B receptor I183A mutant by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID82355K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.12002Journal of medicinal chemistry, Aug-29, Volume: 45, Issue:18
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID721751Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1056957Agonist activity at human 5-HT3B receptor W90C mutant by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056977Binding affinity to human 5-HT3B receptor H73A mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID61534Binding affinity towards D2 receptor in rat was evaluated2002Bioorganic & medicinal chemistry letters, Jan-21, Volume: 12, Issue:2
Synthesis and pharmacology of isoquinuclidine derivatives as 5-HT(3) ligands.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1056969Agonist activity at human 5-HT3A receptor Y73F mutant by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID4328Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Synthesis and biochemical evaluation of tritium-labeled 1-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxa mide, a useful radioligand for 5HT3 receptors.
AID1889692Antagonist activity at 5-HT3 receptor in guinea-pig ileum assessed as inhibition of 5HT-induced contraction2022European journal of medicinal chemistry, Mar-15, Volume: 232Novel D
AID537659Binding affinity to 5HT3A receptor2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Computational analysis of ligand recognition sites of homo- and heteropentameric 5-HT3 receptors.
AID6084Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
5-Hydroxytryptamine (5-HT3) receptor antagonists. 2. 1-Indolinecarboxamides.
AID79521Single-point analysis using 5(10e-9) M concentration of the antagonist (pA2= -log([B]/concentration ratio-1); [B] =concentration of the antagonist).1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
Benzimidazole derivatives. 2. Synthesis and structure-activity relationships of new azabicyclic benzimidazole-4-carboxylic acid derivatives with affinity for serotoninergic 5-HT(3) receptors.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID183117Inhibitory dose causing inhibition of increase in 5-HT induced defecation by sc administration 1 to 10 mg/kg1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
5-HT3 receptor antagonists. 3. Quinoline derivatives which may be effective in the therapy of irritable bowel syndrome.
AID183120Inhibitory dose causing inhibition of increase in thyrotropin-releasing hormone (TRH) induced defecation by sc administration at 1 mg/kg1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
5-HT3 receptor antagonists. 3. Quinoline derivatives which may be effective in the therapy of irritable bowel syndrome.
AID14400Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors.
AID145856In vitro Binding affinity towards alpha-1-beta-1-gamma-delta nAChR was determined; not done2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist.
AID6137Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
Benzoxazole derivatives as novel 5-HT3 receptor partial agonists in the gut.
AID6292In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation.
AID1056990Binding affinity to human 5-HT3B receptor I183A mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID5964Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site.
AID6136Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.1993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
5-HT3 receptor antagonists. 2. 4-Hydroxy-3-quinolinecarboxylic acid derivatives.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1056961Agonist activity at human 5-HT3A receptor D165K mutant by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID5290Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Synthesis and biochemical evaluation of tritium-labeled 1-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxa mide, a useful radioligand for 5HT3 receptors.
AID1056968Agonist activity at human 5-HT3A receptor Y73S mutant by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056984Binding affinity to human 5-HT3A receptor F130Y mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID420668Inhibition of human ERG in MCF7 cells2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID177157In vivo effective dose against Bezold-Jarisch reflex evoked by 5-HT in urethane-anesthetized rats1997Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4
New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1056978Binding affinity to human wild type 5-HT3A/5-HT3B receptor expressed in HEK293 cells after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID183121Inhibitory dose causing inhibition of restraint stress induced defecation by oral administration1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
5-HT3 receptor antagonists. 3. Quinoline derivatives which may be effective in the therapy of irritable bowel syndrome.
AID4702Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Synthesis and biochemical evaluation of tritium-labeled 1-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxa mide, a useful radioligand for 5HT3 receptors.
AID122492Transition time (time required to evacuate the glass bead) in the distal colon in mice at dose 30 mg/kg1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
Benzoxazole derivatives as novel 5-HT3 receptor partial agonists in the gut.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID721752Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID146789In vitro Binding affinity towards alpha-7 nAChR was determined2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist.
AID5891Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
5-HT3 antagonists derived from aminopyridazine-type muscarinic M1 agonists.
AID6285Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site.
AID72054Antiemetic potency was tested against cisplatin-induced emetic latency period in ferret after oral administration1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Development of high-affinity 5-HT3 receptor antagonists. 2. Two novel tricyclic benzamides.
AID59335-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
5-Hydroxytryptamine (5-HT3) receptor antagonists. 1. Indazole and indolizine-3-carboxylic acid derivatives.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1056983Binding affinity to human 5-HT3A receptor S163A mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056988Binding affinity to human 5-HT3A receptor Y73F mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID178568Effective dose required to inhibit 5-HT- mediated bradycardia in rat after intravenous administration1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Synthesis and biochemical evaluation of tritium-labeled 1-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxa mide, a useful radioligand for 5HT3 receptors.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID72057Antiemetic activity (oral administration) against cisplatin-induced emesis in ferret, as the dose required to increase latency to first emetic bout by 50%1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides.
AID122488Transition time (time required to evacuate the glass bead) in the distal colon in mice at dose 0.3 mg/kg1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
Benzoxazole derivatives as novel 5-HT3 receptor partial agonists in the gut.
AID146640In vitro Binding affinity towards Nicotinic acetylcholine receptor alpha4-beta2 was determined2001Bioorganic & medicinal chemistry letters, Feb-12, Volume: 11, Issue:3
The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1056955Agonist activity at human 5-HT3B receptor Y143A mutant by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID6298pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Synthesis and biochemical evaluation of tritium-labeled 1-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxa mide, a useful radioligand for 5HT3 receptors.
AID6132Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.
AID6027Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site.
AID1056982Binding affinity to human 5-HT3A receptor S163T mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID177426Compound was evaluated for the inhibition of 5-HT induced bradycardia [Bezold-Jarisch (BJ) reflex test] in rats at 5 min1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
5-HT3 receptor antagonists. 1. New quinoline derivatives.
AID1056960Agonist activity at human 5-HT3A receptor W183C mutant by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056985Binding affinity to human 5-HT3A receptor F130A mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056981Binding affinity to human 5-HT3A receptor D165A mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056963Agonist activity at human 5-HT3A receptor S163T mutant by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID72056Antiemetic activity (intravenous administration) against cisplatin-induced emesis in ferret, as the dose required to reduce emetic episodes to 50% of control value1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID71931Antiemetic activity (intravenous administration) against cisplatin-induced emesis in ferret, as the dose required to increase latency to first emetic bout by 100%1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1056959Agonist activity at human wild type 5-HT3A/5-HT3B receptor expressed in HEK293 cells by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1056964Agonist activity at human 5-HT3A receptor S163A mutant by FLIPR assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID72058Antiemetic activity (oral administration) against cisplatin-induced emesis in ferret, as the dose required to reduce emetic episodes to 50% of control value1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides.
AID5893Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane1998Journal of medicinal chemistry, Feb-26, Volume: 41, Issue:5
Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 1. Mapping the central 5-HT3 receptor binding site by arylpiperazine derivatives.
AID178008Effective dose causing reduction of serotonin effect at 5 min administered iv in Bezold-Jarisch reflex test1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
5-HT3 receptor antagonists. 3. Quinoline derivatives which may be effective in the therapy of irritable bowel syndrome.
AID1056976Binding affinity to human 5-HT3B receptor W90C mutant after 24 hrs by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID183119Inhibitory dose causing inhibition of increase in castor oil induced diarrhea by oral administration at 1 ml/rat1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
5-HT3 receptor antagonists. 3. Quinoline derivatives which may be effective in the therapy of irritable bowel syndrome.
AID183110Inhibition of wrap-restraint stress-induced colonic propulsion measured by the time required to expel a teflon ball inserted 3 cm into the rat colon1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
5-HT3 receptor antagonists. 3. Quinoline derivatives which may be effective in the therapy of irritable bowel syndrome.
AID4875Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
Synthesis and biochemical evaluation of tritium-labeled 1-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxa mide, a useful radioligand for 5HT3 receptors.
AID122489Transition time (time required to evacuate the glass bead) in the distal colon in mice at dose 1 mg/kg1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
Benzoxazole derivatives as novel 5-HT3 receptor partial agonists in the gut.
AID239587Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortical membrane2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Further studies on the interaction of the 5-hydroxytryptamine3 (5-HT3) receptor with arylpiperazine ligands. development of a new 5-HT3 receptor ligand showing potent acetylcholinesterase inhibitory properties.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID493017Wombat Data for BeliefDocking2002Journal of medicinal chemistry, Aug-29, Volume: 45, Issue:18
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,140)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (1.49)18.7374
1990's525 (46.05)18.2507
2000's306 (26.84)29.6817
2010's233 (20.44)24.3611
2020's59 (5.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 85.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index85.38 (24.57)
Research Supply Index4.09 (2.92)
Research Growth Index5.94 (4.65)
Search Engine Demand Index145.65 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (85.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials466 (40.56%)5.53%
Trials0 (0.00%)5.53%
Reviews100 (8.70%)6.00%
Reviews1 (1.69%)6.00%
Case Studies29 (2.52%)4.05%
Case Studies0 (0.00%)4.05%
Observational9 (0.78%)0.25%
Observational0 (0.00%)0.25%
Other545 (47.43%)84.16%
Other58 (98.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (91)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Comparative Electrocardiographic Effects of Intravenous Ondansetron and Granisetron in Patients Undergoing Surgery for Carcinoma Breast: A Prospective Single Blind Randomised Trial [NCT01352130]Phase 470 participants (Actual)Interventional2007-03-31Completed
A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Granisetron Hydrochloride 1 mg Tablets Under Fasting Conditions [NCT00618254]32 participants (Actual)Interventional2005-03-31Completed
A Randomized, Single Administration, Double-blind, Parallel-group Phase 2 Dose Finding Study to Assess the Efficacy, Tolerability, and Safety of TRG (Intranasal Granisetron) in Patients With Chemotherapy-induced Nausea and Vomiting (CINV) Associated With [NCT00787566]Phase 268 participants (Actual)Interventional2008-10-31Completed
A Phase I Open-label Study to Evaluate the Effect of Multiple Doses of AZD1775 on the Pharmacokinetics of Substrates for CYP3A, CYP2C19, CYP1A2 and to Provide Data on the Effect of AZD1775 on QT Interval in Patients With Advanced Solid Tumours [NCT03333824]Phase 133 participants (Actual)Interventional2017-12-01Completed
Effect of Granisetron on Usage of Sympathomimetics During Caesarean Section - a Retrospective Analysis [NCT03318536]240 participants (Actual)Observational2017-10-05Completed
Effect of Intravenous Granisetron on Incidence and Severity of Intrathecal Morphine Induced Pruritus in Elective Cesarean Section [NCT03483870]Phase 280 participants (Actual)Interventional2018-06-01Completed
The Serotonin Receptor Type 3 Antagonist Granisetron as a New Treatment Approach for Patients With Chronic Myofascial Pain in the Orofacial Muscles [NCT02230371]Phase 440 participants (Actual)Interventional2007-03-31Completed
A Single-Dose, Comparative Bioavailability Study of Two Formulations of Granisetron 1 mg Tablets Under Fasting Conditions [NCT00834717]Phase 140 participants (Actual)Interventional2005-09-30Completed
Cabazitaxel in Combination With Prednisolone With Primary Prophylaxis With PEG-G-CSF for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer [NCT02441894]Phase 421 participants (Actual)Interventional2015-04-30Completed
A Randomized, Active-control, Double-blind, Double-dummy, Parallel-group, Multi-center Study to Assess the Efficacy and Safety of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting Associated With the Administratio [NCT01937156]Phase 3313 participants (Actual)Interventional2013-08-31Completed
Comparison of Granisetron Versus Midazolam and Thier Combination for Prophylaxis of Postoperative Nausea and Vomiting in Laparoscopic Surgery in Children [NCT03483350]Phase 390 participants (Anticipated)Interventional2018-03-31Not yet recruiting
A Single-Dose, Comparative Bioavailability Study of Two Formulations of Granisetron 1 mg Tablets Under Fed Conditions [NCT00834522]Phase 180 participants (Actual)Interventional2005-07-31Completed
Ultrasound Assessment of the Effect of Metoclopramide Versus Granisetron on Gastric Volume in Patients Undergoing Caesarean Section [NCT04290026]Early Phase 190 participants (Anticipated)Interventional2021-04-01Recruiting
A Phase I Pharmacokinetic Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers [NCT02563951]Phase 150 participants (Actual)Interventional2015-09-30Completed
A Comparative Study of 1mg and 3 mg of Granisetron in the Prevention of Postoperative Nausea and Vomiting in Strabismus Ophthalmic Surgeries During General Anesthesia [NCT04918862]Phase 3210 participants (Actual)Interventional2021-01-08Completed
An Open-Label, Randomized, Single-Center, Two-period, Two-sequence Cross-over Study to Assess the Bioequivalence of a Single 6-day Application of SP-01 (Granisetron Patch) Manufactured at Two Different Sites in Healthy Chinese Subjects [NCT05075876]Phase 166 participants (Actual)Interventional2021-10-13Completed
Drug Disposition and Nephrotoxicity [NCT03817970]Phase 372 participants (Anticipated)Interventional2019-11-15Recruiting
Phase II Study of Rituximab in Combination With Methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, Vincristine, Ifosfamide, Etoposide, Cytarabine and Mesna (MACLO/IVAM) in Patients With Previously Untreated Mantle Cell Lymphoma [NCT00450801]Phase 222 participants (Actual)Interventional2004-04-30Completed
A Two Part Study Investigating the Safety and pk of Single Ascending Doses of Staccato Granisetron (AZ-010) and Crossover Comparison of the Pharmacokinetics and Safety of AZ-010 and Intravenous Granisetron in Healthy Volunteers [NCT04200092]Phase 136 participants (Actual)Interventional2019-11-04Completed
A Phase II, Multicenter,Double-Blind, Randomized Trial of Palonosetron Compared With Granisetron in Preventing Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting in the Chinese Cancer Patients [NCT00666783]Phase 2208 participants (Actual)InterventionalCompleted
A Study to Assess the Pharmacokinetics, Tolerability and Safety of the co-Administration of Sancuso® (Transdermal Granisetron) and Intravenous Granisetron in Healthy Subjects [NCT00873197]Phase 112 participants (Actual)Interventional2009-04-30Completed
A Phase III, Randomized, Multi-center, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Study the Safety, Tolerability and Efficacy of MK0869/Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated Wit [NCT00952341]Phase 3421 participants (Actual)Interventional2009-08-25Completed
A Single-Blind, Randomized, Parallel Trial to Define the ECG Effects of Sancuso® (Granisetron Transdermal System) Compared to Placebo and Moxifloxacin in Healthy Men and Women [NCT00890565]Phase 1240 participants (Actual)Interventional2009-05-31Completed
An Investigation on the Effect of Age and BMI on the Pharmacokinetics of Transdermal Granisetron [NCT00868764]Phase 160 participants (Anticipated)Interventional2009-04-30Completed
Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Breakthrough Nausea and Vomiting (CINV) in Patients Receiving Moderately or Highly Emetogenic Chemotherapy: A Phase II Clinical Trial [NCT04085393]Phase 20 participants (Actual)Interventional2020-08-15Withdrawn(stopped due to sponsor withdrew study)
A Randomized, Double-blind Study of 2 Dose Levels of Kytril on the Prevention of Post-operative Nausea and Vomiting in Pediatric Patients Undergoing Surgery With General Anesthesia [NCT00231478]Phase 4171 participants (Actual)Interventional2007-04-30Completed
An Open-label, Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of Chronic Graft Versus Host Disease After TLI/ARG Nonmyeloablative Allogeneic Stem Cell Transplantation [NCT00186628]Phase 236 participants (Actual)Interventional2005-06-30Completed
Pilot Study Evaluating Aprepitant (MK-869) for Prevention of Nausea & Vomiting Secondary to High Dose Cyclophosphamide Administered to Patients Underging Undergoing Peripheral Hematopoietic Progenitor Cell Mobilization Prior to Autologous Transplantation [NCT00293384]40 participants (Actual)Interventional2004-10-31Completed
The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy [NCT01909856]Phase 292 participants (Actual)Interventional2011-10-31Completed
Attenuation of Spinal Induced Hypotension With Granisetron in Type I Diabetic Parturients [NCT03091881]Phase 468 participants (Actual)Interventional2018-03-01Completed
Phase II Randomized Cross-over Study to Evaluate Patient Satisfaction, Efficacy and Compliance of Granisetron Patch vs. Ondansetron in Malignant Glioma Patients Receiving Standard Radiotherapy (RT) and Concomitant Temozolomide (TMZ) [NCT01952886]Phase 20 participants (Actual)InterventionalWithdrawn(stopped due to Lack of approval and funding from company)
A Study to Investigate the Efficacy and Tolerability of Two Dose Levels of Lerisetron Compared With Granisetron in Patients Receiving Radiotherapy for Stage I Seminoma [NCT00004219]Phase 3150 participants (Anticipated)InterventionalActive, not recruiting
A Phase I Study to Evaluate the Effect of External Heat on the Pharmacokinetics of a Transdermal Granisetron Patch in Healthy Subjects [NCT01073696]Phase 116 participants (Actual)Interventional2010-03-31Completed
Intravenous Granisetron Provides Less Ephedrine Requirement Than Ondansetron in Patients Undergoing Cesarean Section With Spinal Anesthesia: A Randomised Placebo-controlled Trial [NCT04613726]Phase 3120 participants (Actual)Interventional2018-12-03Completed
Granisetron vs Granisetron and Dexamethasone on the Reduction of Postoperative Nausea and Vomiting After Caesarean Section With Intrathecal Morphine: A Randomized Controlled Trial [NCT04570592]Phase 2126 participants (Anticipated)Interventional2020-10-01Recruiting
A Comparative Study Between Palonosetron vs the Combination of Granisetron and Dexamethasone in Preventing Postoperative Nausea and Vomiting in Laparoscopic Cholecystectomy. [NCT06043336]Phase 4134 participants (Actual)Interventional2018-05-10Completed
Intravenous Clonidine Versus Granisetron for Prevention of Post Spinal Anesthesia Shivering in Cesarean Section [NCT06031090]Phase 2186 participants (Anticipated)Interventional2023-03-05Recruiting
A Pilot Study to Evaluate the Efficacy of Fosaprepitant and Granisetron Transdermal System for the Prevention of Acute and Delayed Nausea and Vomiting in Breast Cancer Patients and to Identify Predictors of Response [NCT01649258]Phase 129 participants (Actual)Interventional2012-09-04Terminated(stopped due to Lack of Efficacy)
Prophylactic Granisetron for the Prevention of Spinal Induced Shivering During Cesarean Section: a Prospective Double Blind Dose Ranging Clinical Study [NCT02588547]Phase 2212 participants (Actual)Interventional2015-11-30Completed
Efficacy and Safety of Granisetron Transdermal Patch System for Prevention of Chemotherapy-induced Delayed Nausea and Vomiting by CapeOX:A Single-Arm, Open-Label, Phase II Study. [NCT05325190]Phase 257 participants (Anticipated)Interventional2021-10-10Recruiting
Granisetron Transdermal Delivery System for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents: a Single-center, Single-arm, Phase II Trial [NCT04472143]Phase 260 participants (Anticipated)Interventional2020-07-18Recruiting
A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Granisetron Hydrochloride 1 mg Tablets Under Fed Conditions [NCT00618111]32 participants (Actual)Interventional2005-03-31Completed
Using Pharmacogenomics (PGx) Results to Guide Post-operative Nausea and Vomiting (PONV) Treatment Practices: A Pilot Study [NCT03503292]Phase 492 participants (Actual)Interventional2018-05-02Completed
[NCT00502437]0 participants InterventionalNot yet recruiting
An Open-Label, Three-Part, Two Period, Single Sequence Study to Assess the Pharmacokinetic Interaction Between Repeat Doses of Oral Casopitant and Repeat Oral Doses of Dolasetron, Granisetron or Rosiglitazone When Co-Administered in Healthy Adult Subjects [NCT00511823]Phase 116 participants (Actual)Interventional2007-07-23Completed
MyRisk: Efficacy and Safety Evaluation of Oral Akynzeo® in Patients Receiving MEC at High Risk of Developing CINV Based on a Prediction Tool: A Multinational and Multicenter Study [NCT04817189]Phase 4530 participants (Anticipated)Interventional2021-02-01Recruiting
Feasibility Study to Compare 2 Strategies of Treatment Algorithm for Treating Nausea and or Vomiting in the Palliative Phase of Cancer Care [NCT03017391]Phase 420 participants (Anticipated)Interventional2017-01-31Not yet recruiting
The Comparison of the Analgesic Effects of Dezocine and Sufentanil in Patient-controlled Analgesia After Laryngectomy [NCT06000137]129 participants (Actual)Interventional2022-02-10Completed
Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients Treated With Platinum Based Chemotherapy [NCT00450853]Phase 231 participants (Actual)Interventional2005-04-30Completed
A Phase II,Multicenter,Randomized,Double-blind,Cross-over Study of Palonosetron Compared With Granisetron in Prevention of Chemotherapy-induced Nausea and Vomiting in Asian Population [NCT00503386]Phase 2144 participants (Actual)Interventional2006-04-30Completed
A Randomized Phase II Trial of Acupressure and Acustimulation Wrist Bands for the Prevention of Chemotherapy-Induced Nausea and Vomiting [NCT00003817]Phase 2700 participants (Anticipated)Interventional1999-10-31Completed
Adjunctive Granisetron Therapy in Patients With Sepsis or Septic Shock:A Single-center, Randomized, Controlled, Single-blind Clinical Trial [NCT03924518]Phase 2154 participants (Actual)Interventional2019-04-25Completed
Treatment of Delayed Nausea: What Works Best? [NCT00020657]Phase 30 participants Interventional2001-07-31Completed
A Phase 4, Open-Label Safety Study of Repeat Doses of SUSTOL in Adult Subjects Receiving Chemotherapy [NCT05434663]Phase 4300 participants (Anticipated)Interventional2022-07-06Active, not recruiting
Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial [NCT00475085]Phase 31,021 participants (Actual)Interventional2006-12-31Completed
ApRepitant in Combination With Granisetron and Dexamethasone versUs Granisetron and dexamEthasone for the Prevention of Vomiting in Patients With HAIC Therapy for Hepatocellular Carcinoma: a Randomized Controlled Study (ARGUE) [NCT05711823]Phase 3300 participants (Anticipated)Interventional2023-07-01Not yet recruiting
A Randomized, Open-Label, Replicate Treatment, 2-Part, Crossover Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches Manufactured at Different Sites. [NCT05027646]Phase 1134 participants (Actual)Interventional2021-07-06Completed
A Randomised, Active Control, Double-Blind, Double-Dummy, Parallel-Group, Multi-National Study to Assess the Efficacy, Tolerability and Safety of the Granisetron Transdermal Delivery System in Chemotherapy-Induced Nausea and Vomiting (CINV) Associated Wit [NCT00273468]Phase 3630 participants Interventional2006-01-31Completed
AMENO-2: Fase IV Study, National, Multiple Centers, Competitive, Randomized, Double Blind, Controlled With Parallel Groups to Determinate the Security, Tolerability and Efficacy of Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nause [NCT00415103]Phase 4196 participants (Anticipated)Interventional2006-11-30Completed
A Double-blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of Ramosetron Plus Dexamethasone Injection for the Prevention of Chemotherapy-Induced Vomiting and Nausea [NCT00272285]Phase 3287 participants (Actual)Interventional2006-01-31Completed
Randomized Study of the Efficacy and Safety of Transdermal Granisetron Compared With Intravenous and Oral Agent in the Control of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy [NCT01662687]Phase 4276 participants (Anticipated)Interventional2012-02-29Recruiting
Oral Granisetron Versus Oral Ondansetron for Treatment of Gastroenteritis: A Randomized Controlled Clinical Trial [NCT06175806]160 participants (Actual)Interventional2023-09-10Completed
Open Label Transdermal Granisetron to Relieve Chronic Nausea and Emesis and to Reduce Medical Utilization in Patients With Gastroparesis [NCT04501211]Phase 20 participants (Actual)Interventional2019-01-01Withdrawn(stopped due to Abandoned due to limited resources)
A Single Arm Study to Evaluate the Control of Chemotherapy Induced Nausea and Vomiting in Non-Hodgkin Lymphoma Patients Receiving R-CHOP. [NCT01843868]130 participants (Anticipated)Interventional2013-05-31Not yet recruiting
Role of Granisetron in Preventing Hypotension After Spinal Anesthesia With Levobupivacaine in Rheumatic Patients Undergoing Elective Cesarean Section: A Randomized Clinical Trial [NCT05314257]Phase 2/Phase 3102 participants (Anticipated)Interventional2022-04-30Recruiting
Comparative Study of Intravenous Single Doses of Palonosetron (PALO) With Granisetron Hydrochloride as a Control in Patients Receiving Highly Emetogenic Chemotherapy [NCT00359567]Phase 31,140 participants (Anticipated)Interventional2006-07-31Completed
Retrospective Comparison of the Effects of Granisetron and Aprepitant in the Prevention of Postoperative Nausea and Vomiting in Laparoscopic Abdominal Surgery [NCT05632224]Phase 460 participants (Anticipated)Interventional2022-11-24Not yet recruiting
Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients:A Superiority Design, Phase III Randomized Trial [NCT04873284]120 participants (Anticipated)Interventional2021-05-01Not yet recruiting
Preoperative Use of Granisetron Transdermal Patch for Prevention of Postoperative Nausea and Vomiting (PONV) in Patients With History of Severe PONV - Open Label, Prospective, Pilot Study [NCT02457195]Phase 250 participants (Actual)Interventional2016-02-29Completed
An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancuso® Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 13 to 17 Years) [NCT01596400]Phase 119 participants (Actual)Interventional2012-05-31Completed
An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancuso® Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 6 to 12 Years) [NCT01596413]Phase 10 participants (Actual)InterventionalWithdrawn(stopped due to The company currently does not have plans to conduct this study)
An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancuso® Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 2 to 5 Years) [NCT01596426]Phase 10 participants (Actual)InterventionalWithdrawn(stopped due to The company currently does not have plans to conduct this study)
Aromatherapy as Prophylaxis for Prevention of Intrathecal Morphine Induced Nausea and Vomiting in Lower Segment Cesarean Section [NCT03434340]155 participants (Actual)Interventional2018-06-26Completed
Sancuso® in Patients With Nausea and/or Vomiting From Gastroparesis: An Open Label Study. [NCT01989221]Phase 314 participants (Actual)Interventional2012-11-30Completed
Pilot Study of Standard Therapy for Prevention of Nausea and Emesis Associated With First Line Post-Operative Intraperitoneal Chemotherapy [NCT01275664]4 participants (Actual)Interventional2011-06-30Terminated(stopped due to Study terminated due to no patient population available)
A Korean Multicenter, Randomized, Double-Blind, Clinical Trial to Evaluate the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapies (MEC, Non-AC R [NCT01636947]Phase 4494 participants (Actual)Interventional2012-12-12Completed
A Double-blind, Multicenter, Parallel Study Comparing the Efficacy and Safety of Kytril Tablets With Placebo, in the Prevention of Nausea and Vomiting During the Days Following Administration of IV Cyclophosphamide-based or Carboplatin-based Chemotherapy [NCT00005024]Phase 30 participants InterventionalActive, not recruiting
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Randomized, Double-Blind, Placebo-Controlled Trial [NCT02116530]Phase 3401 participants (Actual)Interventional2014-08-31Completed
A Randomized, Double-Blind Trial to Compare the Clinical Efficacy and Safety of Granisetron vs. Metoclopramide Combined to Dexamethasone in the Prophylaxis of Chemotherapy-Induced Delayed Emesis [NCT00003213]Phase 3267 participants (Actual)Interventional1996-05-31Completed
Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis [NCT02625181]27,034 participants (Actual)Interventional2016-07-31Completed
Efficacy and Safety of Granisteron Versus Metoclopramide as Prophylaxis Antiemetic in Laparoscopic Cholecystectomy [NCT04899817]Phase 460 participants (Anticipated)Interventional2021-05-31Not yet recruiting
Phase 3, Multicenter, Randomized, Double Blind, Active-Controlled Study of the Safety & Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy (HEC) [NCT01499849]Phase 3532 participants (Actual)Interventional2012-02-29Completed
Granisetron Effect on Hemodynamic Changes and Intubation Condition During Anesthesia Induction in Laparoscopic Cholecystectomy [NCT03180229]Phase 4140 participants (Actual)Interventional2017-05-29Completed
Effects of Ondansetron, Metoclopramide and Granisetron on Perioperative Nausea and Vomiting in Patients Undergone Bariatric Surgery: a Randomized Clinical Trial [NCT05087615]Phase 3130 participants (Actual)Interventional2021-03-01Completed
BMT-08: A Comparative Effectiveness Study of the Efficacy and Safety of Transdermal Granisetron to Ondansetron in the Prevention of Nausea and Vomiting in Patients Undergoing Preparative Chemotherapy and Hematopoietic Stem Cell Transplantation [NCT04150614]Phase 490 participants (Anticipated)Interventional2020-05-14Recruiting
Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation [NCT01536392]Phase 376 participants (Actual)Interventional2012-03-31Completed
A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexameth [NCT02106494]Phase 3942 participants (Actual)Interventional2014-03-31Completed
Aprepitant and Granisetron for the Prophylaxis of Radiation Induced Nausea and Vomiting - A Pilot Study [NCT01183481]Phase 219 participants (Actual)Interventional2011-01-31Terminated(stopped due to Study was stopped due to inadequate accrual.)
A Phase 3, Multicenter, Randomized, Double Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy [NCT01500213]Phase 3555 participants (Actual)Interventional2012-02-29Completed
Granisetron Transdermal Delivery System Versus Palonosetron in the Prevention of Delayed Chemotherapy-induced Nausea and Vomiting: a Phase 3 Non-inferiority Randomized Trial [NCT04912271]Phase 3140 participants (Anticipated)Interventional2021-06-10Not yet recruiting
Phase 3, Multicenter, Randomized, Double Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderately Emetogenic Chemotherapy [NCT01500226]Phase 31,369 participants (Actual)Interventional2012-02-29Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00186628 (4) [back to overview]Chronic Graft-vs-Host Disease (cGvHD)
NCT00186628 (4) [back to overview]Incidence of Relapse
NCT00186628 (4) [back to overview]Overall Survival
NCT00186628 (4) [back to overview]Mortality
NCT00231478 (4) [back to overview]Adverse Experiences
NCT00231478 (4) [back to overview]Number of Patients With no Vomiting
NCT00231478 (4) [back to overview]Number of Patients With no Vomiting
NCT00231478 (4) [back to overview]Time to First Vomiting Episode
NCT00293384 (4) [back to overview]Delayed Vomiting Controlled
NCT00293384 (4) [back to overview]Overall Nausea Controlled
NCT00293384 (4) [back to overview]Proportion of Participants With Controlled Acute Vomiting
NCT00293384 (4) [back to overview]Toxicity Grade 3, 4, or 5
NCT00450801 (4) [back to overview]Overall Survival Rate
NCT00450801 (4) [back to overview]Number of Patients Experiencing Adverse Events.
NCT00450801 (4) [back to overview]Response Rate
NCT00450801 (4) [back to overview]Progression-free Survival Rate
NCT00475085 (1) [back to overview]Home Record: Severity of Delayed Nausea
NCT00787566 (1) [back to overview]Percentage of Patients With Complete Control
NCT00834522 (3) [back to overview]AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)]
NCT00834522 (3) [back to overview]AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)]
NCT00834522 (3) [back to overview]Cmax (Maximum Observed Concentration)
NCT00834717 (3) [back to overview]Auc0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)]
NCT00834717 (3) [back to overview]AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)]
NCT00834717 (3) [back to overview]Cmax (Maximum Observed Concentration)
NCT00952341 (8) [back to overview]Proportion of Participants With No Vomiting in the Delayed Phase of Cycle 1
NCT00952341 (8) [back to overview]Proportion of Participants With No Vomiting in the Overall Phase of Cycle 1
NCT00952341 (8) [back to overview]Time to First Vomiting Episode in Cycle 1
NCT00952341 (8) [back to overview]Proportion of Participants With Complete Response 120 Hours Following Initiation of High-dose Cisplatin Chemotherapy in the Overall Phase of Cycle 1
NCT00952341 (8) [back to overview]Proportion of Participants With Complete Response in the Acute Phase of Cycle 1
NCT00952341 (8) [back to overview]Proportion of Participants With Complete Response in the Delayed Phase of Cycle 1
NCT00952341 (8) [back to overview]Proportion of Participants With No Impact on Daily Life in Cycle 1
NCT00952341 (8) [back to overview]Proportion of Participants With No Vomiting in the Acute Phase of Cycle 1
NCT01183481 (5) [back to overview]Control Rate of Delayed Phase Nausea, Vomiting, and Retching in Patients Undergoing Multiple Fraction Radiotherapy
NCT01183481 (5) [back to overview]Control Rate of Delayed Phase Nausea, Vomiting, and Retching in Patients Undergoing Single Fraction Radiotherapy
NCT01183481 (5) [back to overview]Control Rate of Acute Phase Nausea, Vomiting, and Retching in Patients Undergoing Single Fraction Radiotherapy
NCT01183481 (5) [back to overview]The Proportion of Patients Experiencing no Vomiting and no Nausea, Without Use of Any Rescue Antiemetic Medication(s), From Days 2-10 Following the Radiation Therapy (Delayed RINV).
NCT01183481 (5) [back to overview]Control Rate of Acute Phase Nausea, Vomiting, and Retching in Patients Undergoing Multiple Fraction Radiotherapy
NCT01275664 (2) [back to overview]Number of Participants With Complete Control Defined as no Vomiting and no Use of Rescue Medications (for Nausea or Emesis)
NCT01275664 (2) [back to overview]Frequency of Adverse Effects as Assessed by the NCI CTCAE v 4.0
NCT01499849 (3) [back to overview]Overall Response Rate
NCT01499849 (3) [back to overview]Acute Phase Response
NCT01499849 (3) [back to overview]No Emetic Episodes and No Rescue Medication
NCT01500213 (3) [back to overview]Overall Response Rate
NCT01500213 (3) [back to overview]No Emetic Episodes and No Rescue Medication
NCT01500213 (3) [back to overview]Acute Phase Response
NCT01500226 (3) [back to overview]Overall Response Rate
NCT01500226 (3) [back to overview]No Emetic Episodes and No Rescue Medication
NCT01500226 (3) [back to overview]Acute Phase Response
NCT01536392 (2) [back to overview]Percentage of Participants With Response Rate to Anti-Emetic Therapy Days 4-7 Each Chemotherapy Cycle
NCT01536392 (2) [back to overview]Percentage of Participants With Response Rate to Anti Emetic Therapy 0-24 Hours Each Chemotherapy Cycle
NCT01636947 (8) [back to overview]Percentage of Participants With No Impact on Daily Life - Overall Stage
NCT01636947 (8) [back to overview]Percentage of Participants With No Vomiting and No Significant Nausea - Overall Stage
NCT01636947 (8) [back to overview]Percentage of Participants With One or More Clinical Adverse Event
NCT01636947 (8) [back to overview]The Percentage of Participants With No Vomiting - Overall Stage
NCT01636947 (8) [back to overview]Number of Participants With No Use of a Rescue Therapy - Overall, Acute, and Delayed Stages
NCT01636947 (8) [back to overview]Percentage of Participants With a Complete Response - Overall, Acute, and Delayed Stages
NCT01636947 (8) [back to overview]Percentage of Participants With No Vomiting - Acute and Delayed Stages
NCT01636947 (8) [back to overview]Number of Emetic Events - Overall Stage
NCT01989221 (2) [back to overview]GCSI-DD Total Composite Symptom Scores.
NCT01989221 (2) [back to overview]Total Gastrointestinal Nausea and Vomiting Symptom Index
NCT02106494 (5) [back to overview]Delayed Complete Control (CC) Rate
NCT02106494 (5) [back to overview]Delayed Phase Complete Response (CR) Rate
NCT02106494 (5) [back to overview]Overall Complete Control Rate
NCT02106494 (5) [back to overview]Overall Complete Response Rate
NCT02106494 (5) [back to overview]Rate of No Emetic Episodes
NCT02116530 (5) [back to overview]Mean Scores of Potential Toxicities Related to Olanzapine as Measured by the Nausea and Vomiting Daily Diary/Questionnaire
NCT02116530 (5) [back to overview]Frequency of Rescue Medication
NCT02116530 (5) [back to overview]Proportion of Patients With no Nausea
NCT02116530 (5) [back to overview]Proportion of Patients With Complete Response
NCT02116530 (5) [back to overview]Median Nausea Scores
NCT02457195 (1) [back to overview]Number of Participants With Complete Response (CR), No PONV Symptoms, Nausea
NCT02625181 (4) [back to overview]Time to Discharge From the Postanesthesia Care Unit (PACU)
NCT02625181 (4) [back to overview]The Number of Prophylactic Interventions for PONV
NCT02625181 (4) [back to overview]PONV Incidence: Number of Participants With Postoperative Nausea and Vomiting
NCT02625181 (4) [back to overview]Adherence to PONV Guidelines
NCT03503292 (2) [back to overview]Episodes of Postoperative Vomiting
NCT03503292 (2) [back to overview]Episodes of Postoperative Nausea

Chronic Graft-vs-Host Disease (cGvHD)

The cumulative percentage of participants who develop chronic graft-vs-host disease (cGvHD). Chronic cGvHD was defined as at least one instance of a clinically-accepted marker for cGvHD (see Filipovich, et al. Biology of Blood and Marrow Transplantation. 2005;11:945-955) (NCT00186628)
Timeframe: 4 years

Interventionpercentage of participants (Number)
Prophylactic Rituximab20

[back to top]

Incidence of Relapse

Subjects who Relapsed following after Allogeneic HSCT (NCT00186628)
Timeframe: 4 years

InterventionParticipants (Count of Participants)
Prophylactic Rituximab18

[back to top]

Overall Survival

(NCT00186628)
Timeframe: 4 years

InterventionPercentage of participants by disease (Number)
Prophylactic Rituximab (CLL Patients)73
Prophylactic Rituximab (MCL Patients)69

[back to top]

Mortality

Number of participants who died within 100 days and within 1 year, non-relapse and associated with relapse. (NCT00186628)
Timeframe: Day 100 and 1 year

InterventionParticipants (Number)
Mortality within 100 days, all causesNonrelapse mortality within 1 yearRelapse + mortality within 1 year
Prophylactic Rituximab012

[back to top]

Adverse Experiences

The adverse events are captured in the AE and SAE section of this database (NCT00231478)
Timeframe: infusion to 15 days post treatment

InterventionNumber of participants assessed (Number)
Granisetron 20 ug/kg79
Granisetron 40 ug/kg78

[back to top]

Number of Patients With no Vomiting

No vomiting describes no emesis during the first 24 hours (NCT00231478)
Timeframe: 0-24h after time of extubation

Interventionparticipants (Number)
Granisetron 20 ug/kg49
Granisetron 40 ug/kg50

[back to top]

Number of Patients With no Vomiting

Number of patients with no vomiting is described as no emesis up to 2 hours after surgery (NCT00231478)
Timeframe: 0-2h after end of surgery (time of extubation)

Interventionparticipants (Number)
Granisetron 20 ug/kg61
Granisetron 40 ug/kg69

[back to top]

Time to First Vomiting Episode

Time to first vomiting is described as the first event of emesis in hours. Subjects not having a vomiting episode are censored at the total length of time (in hours) between the time of extubation and time of the 24 hour follow-up. (NCT00231478)
Timeframe: 0-24h after time of extubation

Interventionhours (Mean)
Granisetron 20 ug/kg18.0
Granisetron 40 ug/kg17.8

[back to top]

Delayed Vomiting Controlled

(NCT00293384)
Timeframe: at 25-120 hours

Interventionparticipants (Number)
Aprepitant, Dexamethasone, Cytoxan & Kytril22

[back to top]

Overall Nausea Controlled

(NCT00293384)
Timeframe: at 0-120 hours

Interventionparticipants (Number)
Aprepitant, Dexamethasone, Cytoxan & Kytril31

[back to top]

Proportion of Participants With Controlled Acute Vomiting

No episodes of vomiting and no rescue medication during first 24 hours after cyclophosphamide administration. (NCT00293384)
Timeframe: at 0-24 hours

Interventionparticipants (Number)
Aprepitant, Dexamethasone, Cytoxan & Kytril20

[back to top]

Toxicity Grade 3, 4, or 5

(NCT00293384)
Timeframe: at 0-120 hours

Interventionparticipants (Number)
Aprepitant, Dexamethasone, Cytoxan & Kytril2

[back to top]

Overall Survival Rate

Percentage of participants who are alive up to five years after receipt of protocol therapy. (NCT00450801)
Timeframe: Up to 5 years

Interventionpercentage of participants (Number)
1-year rate overall survival Rate2-year overall survival Rate3-year overall survival rate4-year overall survival rate5-year overall survival rate
R-MACLO-IVAM-T9696968787

[back to top]

Number of Patients Experiencing Adverse Events.

Number of patients experiencing adverse events during the course of protocol therapy. (NCT00450801)
Timeframe: Up to 5 years

Interventionparticipants (Number)
R-MACLO Cycles22
R-IVAM Cycles22
Thalidomide Therapy19

[back to top]

Response Rate

Percentage of participants achieving complete response (CR) to protocol therapy according to International Working Group Response Criteria for Non-Hodgkin's Lymphoma (NHL) using the CT imaging method. Patients were classified by best tumor response; CR was defined as normalization of the lactate dehydrogenase (LDH), complete disappearance of disease-related symptoms and lymph nodes, and clearance of lymphoma from involved organs; complete response unconfirmed (CRu) as a residual lymph node greater than 1.5 cm in greatest transverse diameter that had regressed by more than 75% or an indeterminate bone marrow examination; partial response (PR) as greater than 50% reduction in the involved lymph nodes, or disappearance of the involved lymph nodes but persistent bone marrow involvement; relapse/progression as new or increased lymph nodes, organomegaly, or reappearance of bone marrow involvement. (NCT00450801)
Timeframe: Up to 5 years

Interventionpercentage of participants (Number)
R-MACLO-IVAM-T100

[back to top]

Progression-free Survival Rate

Percentage of participants achieving progression-free survival at 1, 3 and 5 years after the start of protocol therapy, based upon the International Working Group Response Criteria for Non-Hodgkin's Lymphoma (NHL). Progression is defined as a ≥ 50% increase from nadir in the product of the two largest perpendicular diameters (PPD-size) of any previously identified abnormal node, or appearance of any new lesion. (NCT00450801)
Timeframe: Up to 5 years

Interventionpercentage of participants (Number)
1 year progression-free survival3 year progression-free survival5-year progression-free survival
R-MACLO-IVAM-T917869

[back to top]

Home Record: Severity of Delayed Nausea

1=not at all nauseated to 7=extremely nauseated, therefore higher values are worse (NCT00475085)
Timeframe: average of day 1 afternoon, evening and night, and all of days 2 and 3

Interventionunits on a scale (Mean)
Arm II1.88
Arm III1.65
Arm I1.87
Arm IV1.68

[back to top]

Percentage of Patients With Complete Control

Complete Control is defined as no emetic episodes, no use of rescue medications, and no more than mild nausea as defined by a categorial scale. (NCT00787566)
Timeframe: 24 hours

InterventionPercentage (Number)
0.5 mg of TRG (Intranasal Granisetron)71.4
1.0 mg of TRG (Intranasal Granisetron)76.0
2.0 mg of TRG (Intranasal Granisetron)90.9

[back to top]

AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)]

Bioequivalence based on AUC0-inf (NCT00834522)
Timeframe: Blood samples collected over 72 hour period

Interventionng*h/mL (Mean)
Granisetron130.3581
Kytril®126.9140

[back to top]

AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)]

Bioequivalence based on AUC0-t (NCT00834522)
Timeframe: Blood samples collected over 72 hour period

Interventionng*h/mL (Mean)
Granisetron127.6581
Kytril®124.4104

[back to top]

Cmax (Maximum Observed Concentration)

Bioequivalence based on Cmax (NCT00834522)
Timeframe: Blood samples collected over 72 hour period

Interventionng/mL (Mean)
Granisetron10.4016
Kytril®10.1061

[back to top]

Auc0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)]

Bioequivalence based on AUC0-inf (NCT00834717)
Timeframe: Blood samples collected over 72 hour period

Interventionng*h/mL (Mean)
Granisetron148.5875
Kytril®160.5850

[back to top]

AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)]

Bioequivalence based on AUC0-t (NCT00834717)
Timeframe: Bl;ood samples collected over 36 hour period

Interventionng*h/mL (Mean)
Granisetron145.4357
Kytril®156.0218

[back to top]

Cmax (Maximum Observed Concentration)

Bioequivalence based on Cmax (NCT00834717)
Timeframe: Blood samples collected over 72 hour period

Interventionng/mL (Mean)
Granisetron10.7738
Kytril®11.0935

[back to top]

Proportion of Participants With No Vomiting in the Delayed Phase of Cycle 1

Delayed Phase was defined as 25 to 120 hours following initiation of chemotherapy (NCT00952341)
Timeframe: 25 to 120 hours

InterventionProportion of participants (Number)
Aprepitant (MK-0869)0.740
Placebo0.594

[back to top]

Proportion of Participants With No Vomiting in the Overall Phase of Cycle 1

"Overall Phase was defined as 0 to 120 hours following initiation of chemotherapy.~No vomiting was defined as no vomiting or retching or dry heaves (included participants who received rescue therapy)." (NCT00952341)
Timeframe: 0 to 120 hours

InterventionProportion of participants (Number)
Aprepitant (MK-0869)0.706
Placebo0.570

[back to top]

Time to First Vomiting Episode in Cycle 1

Time from administration of chemotherapy to first vomiting episode. (NCT00952341)
Timeframe: 0 to 120 hours

InterventionHours (Mean)
Aprepitant (MK-0869)77.0
Placebo76.0

[back to top]

Proportion of Participants With Complete Response 120 Hours Following Initiation of High-dose Cisplatin Chemotherapy in the Overall Phase of Cycle 1

"Overall phase was defined as 0 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT00952341)
Timeframe: 0 to 120 hours

InterventionProportion of participants (Number)
Aprepitant (MK-0869)0.696
Placebo0.570

[back to top]

Proportion of Participants With Complete Response in the Acute Phase of Cycle 1

"Acute phase was defined as 0 to 24 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT00952341)
Timeframe: 0 to 24 hours

InterventionProportion of participants (Number)
Aprepitant (MK-0869)0.794
Placebo0.793

[back to top]

Proportion of Participants With Complete Response in the Delayed Phase of Cycle 1

"Delayed phase was defined as 25 to 120 hours following initiation of chemotherapy.~Complete response was defined as no vomiting with no rescue therapy." (NCT00952341)
Timeframe: 25 to 120 hours

InterventionProportion of participants (Number)
Aprepitant (MK-0869)0.740
Placebo0.594

[back to top]

Proportion of Participants With No Impact on Daily Life in Cycle 1

"The Functional Living Index-Emesis is a self-administered, validated emesis & nausea-specific questionnaire. Participants completed the questionnaire 5 days post chemotherapy. It had 9 questions each on nausea and vomiting. No impact of chemotherapy-induced nausea & vomiting (CINV) on daily life was defined as an average item score of >6 on the 7-point scale (i.e., >108 total score). The scale was in the opposite direction for questions 3, 6, 11, 15 & 18. For each question: score ranged from 1 (worst) to 7 (best, i.e., no CINV). Total score range was 7 (worst) to 126 (best)." (NCT00952341)
Timeframe: 0 to 120 hours

InterventionProportion of participants (Number)
Aprepitant (MK-0869)0.705
Placebo0.683

[back to top]

Proportion of Participants With No Vomiting in the Acute Phase of Cycle 1

Acute Phase was defined as 0 to 24 hours following initiation of chemotherapy. (NCT00952341)
Timeframe: 0 to 24 hours

InterventionProportion of participants (Number)
Aprepitant (MK-0869)0.804
Placebo0.798

[back to top]

Control Rate of Delayed Phase Nausea, Vomiting, and Retching in Patients Undergoing Multiple Fraction Radiotherapy

"Percentage of participants experiencing no nausea, vomiting, and retching was assessed.~Assessments of nausea, vomiting, and antiemetic use will be taken daily within 2-10 following the radiation therapy based on patient self-report nausea/vomiting diaries." (NCT01183481)
Timeframe: Days 2-10 following radiotherapy

Interventionpercentage of participants (Number)
Control rate of delayed phase nauseaControl rate of delayed phase vomiting/retching
Aprepitant and Granisetron8383

[back to top]

Control Rate of Delayed Phase Nausea, Vomiting, and Retching in Patients Undergoing Single Fraction Radiotherapy

"Percentage of participants in the single fraction arm experiencing no nausea, vomiting, and retching was assessed.~Assessments of nausea, vomiting, and antiemetic use will be taken daily within 2-10 following the radiation therapy based on patient self-report nausea/vomiting diaries." (NCT01183481)
Timeframe: Days 2-10 following radiotherapy

Interventionpercentage of participants (Number)
Control rate of delayed phase nauseaControl rate of delayed phase vomiting/retching
Aprepitant and Granisetron6285

[back to top]

Control Rate of Acute Phase Nausea, Vomiting, and Retching in Patients Undergoing Single Fraction Radiotherapy

"Percentage of participants experiencing no nausea, vomiting, and retching during the acute phase was assessed.~Assessments of nausea, vomiting, and antiemetic use will be taken daily following the radiation therapy based on patient self-report nausea/vomiting diaries." (NCT01183481)
Timeframe: Day of radiotherapy and 24 hours following

Interventionpercentage of participants (Number)
Control rate of acute phase nauseaControl rate of acute phase vomiting/retching
Aprepitant and Granisetron100100

[back to top]

The Proportion of Patients Experiencing no Vomiting and no Nausea, Without Use of Any Rescue Antiemetic Medication(s), From Days 2-10 Following the Radiation Therapy (Delayed RINV).

Assessments of nausea, vomiting, and antiemetic use will be taken daily within 2-10 following the radiation therapy based on patient self-report nausea/vomiting diaries. (NCT01183481)
Timeframe: Days 2-10 following radiotherapy

Interventionparticipants (Number)
Aprepitant and Granisetron19

[back to top]

Control Rate of Acute Phase Nausea, Vomiting, and Retching in Patients Undergoing Multiple Fraction Radiotherapy

"Percentage of participants in the multiple fraction arm experiencing no nausea, vomiting, and retching was assessed.~Data will be measured by research staff at baseline and patient self-report nausea diaries will be taken on each day within this time frame." (NCT01183481)
Timeframe: During radiotherapy (5 days) and the 24 hours following radiotherapy

Interventionpercentage of participants (Number)
Control rate of acute phase nauseaControl rate of acute phase vomiting/retching
Aprepitant and Granisetron6767

[back to top]

Number of Participants With Complete Control Defined as no Vomiting and no Use of Rescue Medications (for Nausea or Emesis)

Number of participants who had complete control defined by no vomiting (NCT01275664)
Timeframe: During the 6 days following chemotherapy

InterventionParticipants (Count of Participants)
Treatment (Granisetron, Dexamethasone, Aprepitant)1

[back to top]

Frequency of Adverse Effects as Assessed by the NCI CTCAE v 4.0

Adverse events at least possibly related to treatment (NCT01275664)
Timeframe: Up to day 6

InterventionParticipants (Count of Participants)
ConstipationFatigueDiarrheaHyponatremiaAlanine Aminotransferase IncreasedGGT Increased
Treatment (Granisetron, Dexamethasone, Aprepitant)111111

[back to top]

Overall Response Rate

To determine the effect of rolapitant on complete response rates in the overall (0 to 120 hours) phase of CINV. (NCT01499849)
Timeframe: 0 to 120 hours

Interventionpercentage of participants (Number)
Rolapitant + Granisetron + Dexamethasone70.1
Placebo + Granisetron + Dexamethasone56.5

[back to top]

Acute Phase Response

To determine the effect of rolapitant on complete response rates in the acute (0 to 24 hours)phase of CINV (NCT01499849)
Timeframe: 0 to 24 hours

Interventionpercentage of participants (Number)
Rolapitant + Granisetron + Dexamethasone83.7
Placebo + Granisetron + Dexamethasone73.7

[back to top]

No Emetic Episodes and No Rescue Medication

The primary objective of this study is to determine whether administration of rolapitant with granisetron and dexamethasone improves CINV in the delayed phase (>24 to 120 hours) of CINV compared with administration of placebo with granisetron and dexamethasone in subjects receiving HEC. The primary outcome will be based on complete response (defined as no emetic episodes and no rescue medication) in the delayed phase (>24 to 120 hours). (NCT01499849)
Timeframe: >24 to 120 hours post chemotherapy

Interventionpercentage of participants (Number)
Rolapitant + Granisetron + Dexamethasone72.7
Placebo + Granisetron + Dexamethasone58.4

[back to top]

Overall Response Rate

To determine the effect of rolapitant on complete response rate in the overall (0 to 120 hours) phase of CINV. (NCT01500213)
Timeframe: 0 to 120 hours

Interventionpercentage of participants (Number)
Rolapitant + Granisetron + Dexamethasone67.5
Placebo + Granisetron + Dexamethasone60.4

[back to top]

No Emetic Episodes and No Rescue Medication

The primary objective of this study is to determine whether administration of rolapitant with granisetron and dexamethasone improves CINV in the delayed phase (>24 to 120 hours) of CINV compared with administration of placebo with granisetron and dexamethasone in subjects receiving HEC. The primary outcome will be based on complete response (defined as no emesis and no rescue medication) in the delayed phase (>24 to 120 hours). (NCT01500213)
Timeframe: >24 to 120 hours post chemotherapy

Interventionpercentage of participants (Number)
Rolapitant + Granisetron + Dexamethasone70.1
Placebo + Granisetron + Dexamethasone61.9

[back to top]

Acute Phase Response

To determine the effect of rolapitant on complete response rates in the acute (0 to 24 hours) phase of CINV. (NCT01500213)
Timeframe: 0 to 24 hours

Interventionpercentage of participants (Number)
Rolapitant + Granisetron + Dexamethasone83.4
Placebo + Granisetron + Dexamethasone79.5

[back to top]

Overall Response Rate

To determine the effect of rolapitant on complete response rate in the overall (0 to 120 hours) phase of CINV. (NCT01500226)
Timeframe: 0 to 120 hours

Interventionpercentage of participants (Number)
Rolapitant + Granisetron + Dexamethasone68.6
Placebo + Granisetron + Dexamethasone57.8

[back to top]

No Emetic Episodes and No Rescue Medication

The primary objective of this study is to determine whether administration of rolapitant with granisetron and dexamethasone improves CINV in the delayed phase (>24 to 120 hours) of CINV compared with administration of placebo with granisetron and dexamethasone in subjects receiving MEC. The primary outcome will be based on complete response (defined as no emesis and no rescue medication) in the delayed phase (>24 to 120 hours). (NCT01500226)
Timeframe: >24 to 120 hours post chemotherapy

Interventionpercentage of particpants (Number)
Rolapitant + Granisetron + Dexamethasone71.3
Placebo + Granisetron + Dexamethasone61.6

[back to top]

Acute Phase Response

To determine the effect of rolapitant on complete response rates in the acute (0 to 24 hours) phase of CINV. (NCT01500226)
Timeframe: 0 to 24 hours

Interventionpercentage of participants (Number)
Rolapitant + Granisetron + Dexamethasone83.5
Placebo + Granisetron + Dexamethasone80.3

[back to top]

Percentage of Participants With Response Rate to Anti-Emetic Therapy Days 4-7 Each Chemotherapy Cycle

Response defined as no emetic or retching episodes and no rescue medication use during late onset phase (4-7 days post-chemotherapy) measured each cycle. Responses tabulated to 4 items of Morisky Medication Adherence measure for each treatment group by cycle of therapy. Elements summarized of Morrow Assessment of Nausea and Emesis and for pill counts/compliance for each treatment group by cycle of therapy. Descriptive statistics summarize total scores for Osoba Module, used to measure effect of nausea and vomiting on quality of life, for each treatment group by cycle of therapy. Osoba Nausea and Emesis Module; higher scores indicate worse quality of life. Morisky Medication Adherence Scale. Higher scores indicate higher compliance. Morisky Medication Adherence Scale is Yes=0 and No=1 , zero is the lowest level of medication adherence, and 4 is the highest level of medication adherence. (NCT01536392)
Timeframe: Baseline, up to 7 days post-chemotherapy, through 5 cycles of chemotherapy measured each cycle, an average of 6 weeks

Interventionpercentage of participants (Number)
Arm 1: Transdermal Granisetron49.8
Arm 2: Oral Ondansetron39.7

[back to top]

Percentage of Participants With Response Rate to Anti Emetic Therapy 0-24 Hours Each Chemotherapy Cycle

The response rates to anti-emetic therapy (no emetic or retching episodes and no rescue medication use) in the acute (0-24 hours) phase. Responses tabulated to 4 items of Morisky Medication Adherence measure for each treatment group by cycle of therapy. Elements summarized of Morrow Assessment of Nausea and Emesis and for pill counts/compliance for each treatment group by cycle of therapy. Descriptive statistics summarize total scores for Osoba Module, used to measure effect of nausea and vomiting on quality of life, for each treatment group by cycle of therapy. Osoba Nausea and Emesis Module; higher scores indicate worse quality of life. Morisky Medication Adherence Scale. Higher scores indicate higher compliance. Morisky Medication Adherence Scale is Yes=0 and No=1 , zero is the lowest level of medication adherence, and 4 is the highest level of medication adherence. (NCT01536392)
Timeframe: Baseline, up to 24 hours post-chemotherapy, through 5 cycles of chemotherapy measured each cycle, an average of 6 weeks

Interventionpercentage of participants (Number)
Arm 1: Transdermal Granisetron49.8
Arm 2: Oral Ondansetron39.7

[back to top]

Percentage of Participants With No Impact on Daily Life - Overall Stage

"The Functional Living Index-Emesis questionnaire (FLIE) is a validated, participant-reported instrument to measure the impact of chemotherapy-induced nausea and vomiting on daily life. There are 9 nausea-related items and 9 vomiting-related items, each on a 7-point scale. For the purposes of this study, No Impact on daily life was defined as an average item score of >6 on the 7-point scale; a total score >108 indicates no impact on daily life. Overall Stage=0 to 120 hours after initiation of MEC." (NCT01636947)
Timeframe: Day 6

InterventionPercentage of Participants (Number)
Aprepitant Regimen76.8
Control Regimen73.8

[back to top]

Percentage of Participants With No Vomiting and No Significant Nausea - Overall Stage

"Nausea was to be assessed using a 100-mm horizontal visual analogue scale (VAS) located in the participant diary labeled: How much nausea have you had over the last 24 hours? The left end of the scale (0 mm) was labeled no nausea, and the right end of the scale (100 mm) is labeled nausea as bad as it could be. In this study, No Significant Nausea was defined as a VAS nausea rating <25 mm." (NCT01636947)
Timeframe: Days 1 to Day 5

InterventionPercentage of Participants (Number)
Aprepitant Regimen76.4
Control Regimen72.4

[back to top]

Percentage of Participants With One or More Clinical Adverse Event

An adverse event was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the study drug. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition, which is temporally associated with the use of the study drug, is also an adverse event. Nausea and vomiting experienced during Days 1-6 were not counted as adverse events unless they were reported as a serious adverse event. (NCT01636947)
Timeframe: Day 1 through Day 29 (Up to 28 days after first dose of study drug)

InterventionPercentage of Participants (Number)
Aprepitant Regimen56.2
Control Regimen53.2

[back to top]

The Percentage of Participants With No Vomiting - Overall Stage

A vomiting episode was defined as one or more episodes of emesis (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents). No vomiting during the Overall Stage was defined as no episodes of emesis during the 120 hours (Days 1-5) after initiation of moderately emetogenic chemotherapy (MEC). (NCT01636947)
Timeframe: Hour 0 on Day 1 to Day 5 (approximately 120 hours)

InterventionPercentage of Participants (Number)
Aprepitant Regimen77.2
Control Regimen72.0

[back to top]

Number of Participants With No Use of a Rescue Therapy - Overall, Acute, and Delayed Stages

The percentage of participants who used no rescue therapy after initiation of MEC is presented for the Overall, Acute and Delayed Stages. Overall Stage=0 to 120 hours after initiation of MEC. Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC. (NCT01636947)
Timeframe: Day 1 to Day 5

,
InterventionPercentage of Participants (Number)
Overall StageAcute StageDelayed Stage
Aprepitant Regimen84.898.784.8
Control Regimen87.799.288.5

[back to top]

Percentage of Participants With a Complete Response - Overall, Acute, and Delayed Stages

A Complete Response was defined as no vomiting or dry heaves and no use of a rescue therapy. Overall Stage=0 to 120 hours after initiation of MEC. Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC. (NCT01636947)
Timeframe: Hour 0 on Day 1 to Day 5 (approximately 120 hours)

,
InterventionPercentage of Participants (Number)
Overall StageAcute StageDelayed Stage
Aprepitant Regimen73.495.874.3
Control Regimen70.497.971.2

[back to top]

Percentage of Participants With No Vomiting - Acute and Delayed Stages

A vomiting episode was defined as one or more episodes of emesis (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents). Acute Stage=0 to 24 hours after initiation of MEC. Delayed Stage=25 to 120 hours after initiation of MEC. (NCT01636947)
Timeframe: Day 1, Day 2 to Day 5

,
InterventionPercentage of Participants (Number)
Acute StageDelayed Stage
Aprepitant Regimen95.878.5
Control Regimen98.872.4

[back to top]

Number of Emetic Events - Overall Stage

The number of emetic events that occurred during the Overall Stage (0 to 120 hours after initiation of MEC) are presented. (NCT01636947)
Timeframe: Hour 0 on Day 1 to Day 5 (approximately 120 hours)

InterventionNumber of Emetic Events (Number)
Aprepitant Regimen54
Control Regimen68

[back to top]

GCSI-DD Total Composite Symptom Scores.

The Gastroparesis Cardinal Symptom Index Daily Diary (GCSI-DD) was used to capture the severity of symptoms during one week at baseline and two weeks of treatment with GTS. The GCSI-DD includes questions about severity of nausea, early satiety, postprandial fullness, upper abdominal pain, and overall symptoms. Patients rated their symptom severity on a scale of 0 (no symptom), 1 (mild), 2 (moderate), 3 (severe), and 4 (very severe) and recorded the number of vomiting episodes per day. A daily composite score was calculated as the average of the five symptom scores (not including overall symptom severity) with a cap of 4 vomiting episodes per day. (NCT01989221)
Timeframe: Three weeks

Interventionscore on a scale (Mean)
BaselineWeek 1 of TreatmentWeek 2 of Treatment
Placebo Followed by Sancuso1.891.571.34

[back to top]

Total Gastrointestinal Nausea and Vomiting Symptom Index

The Gastroparesis Cardinal Symptom Index Daily Diary (GCSI-DD) was used to capture the severity of symptoms during one week at baseline and at two weeks of treatment with GTS. The GCSI-DD includes questions about severity of nausea, early satiety, postprandial fullness, upper abdominal pain, and overall symptoms. Patients rated their symptom severity on a scale of 0 (no symptom), 1 (mild), 2 (moderate), 3 (severe), and 4 (very severe) and recorded the number of vomiting episodes per day. A daily composite score was calculated as the average of the five symptom scores (not including overall symptom severity) with a cap of 4 vomiting episodes per day. (NCT01989221)
Timeframe: Three weeks

Interventionscore on a scale (Mean)
BaselineWeek 1 of TreatmentWeek 2 of Treatment
Placebo Followed by Sancuso2.311.691.30

[back to top]

Delayed Complete Control (CC) Rate

To determine the effect of APF530 on complete control rates defined as no more than mild nausea, no emetic episodes [vomiting or retching], and no use of rescue medications in the delayed phase (24 to 120 hours) of CINV. (NCT02106494)
Timeframe: 24 - 120 Hours

Interventionpercentage of participants (Number)
APF530 + Fosaprepitant + Dexamethasone60.7
Ondansetron + Fosaprepitant + Dexamethasone53.1

[back to top]

Delayed Phase Complete Response (CR) Rate

Percentage of Participants with no emesis and no rescue medication in patients receiving HEC in the delayed phase (24 to 120 hours) of CINV. (NCT02106494)
Timeframe: 24 - 120 Hours

Interventionpercentage of participants (Number)
APF530 + Fosaprepitant + Dexamethasone64.7
Ondansetron + Fosaprepitant + Dexamethasone56.6

[back to top]

Overall Complete Control Rate

To determine the effect of APF530 on complete control rates defined as no more than mild nausea, no emetic episodes [vomiting or retching], and no use of rescue medications in the overall phase (0 to 120 hours) of CINV. (NCT02106494)
Timeframe: 0 - 120 Hours

Interventionpercentage of participants (Number)
APF530 + Fosaprepitant + Dexamethasone54.7
Ondansetron + Fosaprepitant + Dexamethasone49.6

[back to top]

Overall Complete Response Rate

To determine the effect of APF530 on complete response rates in the overall phase (0 to 120 hours) of CINV. (NCT02106494)
Timeframe: 0 - 120 Hours

Interventionpercentage of participants (Number)
APF530 + Fosaprepitant + Dexamethasone58.4
Ondansetron + Fosaprepitant + Dexamethasone52.9

[back to top]

Rate of No Emetic Episodes

To determine the effect of APF530 on the rate of no emetic episodes (vomiting or retching) in the overall phase (0 to 120 hours) of CINV. (NCT02106494)
Timeframe: 0 - 120 Hours

Interventionpercentage of participants (Number)
APF530 + Fosaprepitant + Dexamethasone82.2
Ondansetron + Fosaprepitant + Dexamethasone79.2

[back to top] [back to top]

Frequency of Rescue Medication

Patients were asked to record daily number of extra nausea/vomiting pills taken because they developed nausea/vomiting in the following categories: None, One, Two, More than two in Nausea and Vomiting Daily Diary Questionnaire. (NCT02116530)
Timeframe: Day 2 to Day 6 after chemotherapy

InterventionParticipants (Count of Participants)
Day 272213840Day 272213839Day 372213839Day 372213840Day 472213839Day 472213840Day 572213840Day 572213839Day 672213839Day 672213840
More than twiceTwiceNoneOnce
Olanzapine156
Placebo117
Olanzapine21
Placebo35
Placebo19
Olanzapine2
Olanzapine158
Placebo124
Olanzapine11
Placebo24
Olanzapine7
Placebo20
Olanzapine4
Placebo10
Olanzapine141
Olanzapine16
Olanzapine10
Placebo17
Olanzapine3
Placebo11
Olanzapine145
Placebo131
Olanzapine19
Placebo23
Olanzapine5
Placebo7
Olanzapine143
Placebo130
Olanzapine12
Placebo16
Placebo14

[back to top]

Proportion of Patients With no Nausea

No nausea was defined as a response of 0 in the nausea item of Nausea and Vomiting Daily Diary/Questionnaire in the acute (0-24 hours), delayed (25-120 hours) and overall (0-120 hours) periods after chemotherapy. (NCT02116530)
Timeframe: 0 to 120 hours after chemotherapy

,
Interventionpercentage of participants (Number)
0-24 hours after chemotherapy25-120 hours after chemotherapy0-120 hours after chemotherapy
Olanzapine73.842.437.3
Placebo45.325.421.9

[back to top]

Proportion of Patients With Complete Response

Complete response was defined as no emetic episodes and no use of rescue medication during the acute (0-24 hours), delayed (25-120 hours) and overall (0-120 hours) periods as measured by the Nausea and Vomiting Daily Diary/Questionnaire. (NCT02116530)
Timeframe: 0 to 120 hours after chemotherapy

,
Interventionpercentage of participants (Number)
0-24 hours after chemotherapy25-120 hours after chemotherapy0-120 hours after chemotherapy
Olanzapine85.766.963.6
Placebo64.652.440.6

[back to top]

Median Nausea Scores

Nausea scores was measured using a visual-analogue scale ranging from 0 (none) to 10 (as bad as it can be). (NCT02116530)
Timeframe: Baseline and Day 2 to Day 6 after chemotherapy

,
Interventionunits on a scale (Median)
BaselineDay 2Day 3Day 4Day 5Day 6
Olanzapine000000
Placebo011111

[back to top]

Number of Participants With Complete Response (CR), No PONV Symptoms, Nausea

Composite measure consisting of complete response (CR), defined as no emetic episode and no rescue medication; the proportions of patients with no emesis and no additional rescue medication in the 120 hours following the completion of surgical procedure. (NCT02457195)
Timeframe: 24 hrs, 48 hrs, 72 hrs and 120 hrs

InterventionParticipants (Count of Participants)
Completed Response : 24 hrsCompleted Response : 48 hrsCompleted Response : 72 hrsCompleted Response : 120 hrsNo PONV symptoms : 24 hrsNo PONV symptoms : 48 hrsNo PONV symptoms : 72 hrsNo PONV symptoms : 120 hrsNausea : 24 hrsNausea : 48 hrsNausea : 72 hrsNausea : 120 hrsVomiting with or without retching : 24 hrsVomiting with or without retching : 48 hrsVomiting with or without retching : 72 hrsVomiting with or without retching : 120 hrsRetching (dry-hives, without vomiting) : 24 hrsRetching (dry-hives, without vomiting) : 48 hrsRetching (dry-hives, without vomiting) : 72 hrsRetching (dry-hives, without vomiting) : 120 hrs
Admnistration of Granisetron82524281825242821117352003100

[back to top]

Time to Discharge From the Postanesthesia Care Unit (PACU)

This is the number of minutes from admission to the PACU until discharge, assessed up to 2 days (NCT02625181)
Timeframe: A specific time frame on the day of surgery: from the start of admission to the PACU to discharge from the PACU

Interventionminutes (Mean)
Baseline Measurement266
CDS Email Recommendations264
CDS Email + Real TIme Recommenations266

[back to top]

The Number of Prophylactic Interventions for PONV

the absolute number of prophylactic interventions applied between the admission of the patient in the holding room until admission to the PACU. (NCT02625181)
Timeframe: A specific time frame on the day of surgery: from the start of admission at the holding room to the end of the anesthetic case

Interventionprophylactic antiemetics administered (Mean)
Baseline Measurement2.196
CDS Email Recommendations2.176
CDS Email + Real TIme Recommenations2.129

[back to top]

PONV Incidence: Number of Participants With Postoperative Nausea and Vomiting

The occurrence of PONV, as defined by the administration of antiemetics in the PACU between admission to PACU and discharge from PACU. (NCT02625181)
Timeframe: PACU recovery period

InterventionParticipants (Count of Participants)
Baseline Measurement139
CDS Email Recommendations1323
CDS Email + Real TIme Recommenations1343

[back to top]

Adherence to PONV Guidelines

PONV guideline adherence: percentage of patients who received the exact number of prophylactic interventions for PONV that were recommended by the decision support. (NCT02625181)
Timeframe: A specific time frame on the day of surgery: the start of admission at the holding room to the end of the anesthetic case

InterventionParticipants (Count of Participants)
Baseline Measurement666
CDS Email Recommendations5260
CDS Email + Real TIme Recommenations5863

[back to top]

Episodes of Postoperative Vomiting

The total number count of post operative vomiting episodes were determined by nursing documentation or by treatment with rescue antinausea medication. (NCT03503292)
Timeframe: 0-48 hours post bariatric surgery

Interventionepisodes (Number)
CYP2D6 Rapid Metabolizer (Granisetron)0
CYP2D6 Normal Metabolizer (Ondansetron)4

[back to top]

Episodes of Postoperative Nausea

The total number count of post operative nausea episodes were determined by nursing documentation or by treatment with rescue antinausea medication. (NCT03503292)
Timeframe: 0-48 hours post bariatric surgery

Interventionepisodes (Number)
CYP2D6 Rapid Metabolizer (Granisetron)0
CYP2D6 Normal Metabolizer (Ondansetron)16

[back to top]